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 i 
Abstract 
Approximately 75% of new molecular entities approved by the Food and Drug Administration 
(FDA) for use in the pharmaceutical industry are found to have poor aqueous solubility. This 
undesirable attribute leads to consequences such as higher doses required to reach therapeutic 
levels, greater vulnerability to food effects, lesser fraction absorbed in the small intestine and 
damage to the environment due to increased quantity of excretion. The addition of an excipient 
(i.e. a FDA approved inactive ingredient) to the molecular structure of an active pharmaceutical 
ingredient (API) through intermolecular bonding is of growing interest because the properties 
of the API can be tuned without further clinical testing. Crystal engineering utilizes the 
knowledge of intermolecular interactions to design new solids with improved properties (e.g. 
solubility, stability, bioavailability, dissolution rates). In this thesis, these techniques are 
applied to increase the solubility of three APIs with low solubility: esomeprazole magnesium, 
curcumin and rufinamide. Through an extensive screening process, novel solid states were 
discovered including a water/butanol solvate of esomeprazole magnesium and a co-amorphous 
mixture comprised of curcumin and folic acid dihydrate. The co-amorphous mixture was found 
to have increased dissolution rate compared to curcumin and can be repositioned as a prenatal 
drug. Characterization of these products include powder and single crystal X-ray diffraction, 
differential scanning calorimetry, thermogravimetric analysis, Fourier Transform infrared 
spectroscopy, solution nuclear magnetic resonance spectroscopy and dynamic vapour sorption. 
Screening of rufinamide did not lead to the discovery of any new forms, but the refined 
molecular structure of the metastable form is reported. 
Keywords 
Crystallization, co-amorphous mixtures, solvates, eutectics, co-crystals, thermal analysis, 
solid-state characterization, dissolution studies 
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Chapter 1  
1 Introduction 
Many of the drugs that are currently or about to be introduced to the market are considered 
to have low water solubility. This leads to some major issues in drug uptake that are costly 
to both pharmaceutical companies and the environment. Crystal engineering is a concept 
that relies on one’s knowledge of intermolecular interactions and uses this knowledge to 
design new materials. A technique exploited by crystal engineering to increase the 
solubility of active pharmaceutical ingredients (APIs) is to incorporate another molecule(s) 
that disrupts its crystal lattice, as illustrated in Figure 1.1. Co-amorphous mixtures, 
eutectics and co-crystals can all be formed when the additional molecules are neutral solids, 
and a solvate occurs solvent molecules are added. 
 
 
Figure 1.1: General scheme of possible solid states formation via excipient addition where 
green is API; blue, yellow and orange are excipients capable of intermolecular bonding; 
and blue is solvent molecules. 
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Creation of these solid states requires extensive screening, which commonly uses both 
computer-based and experimental techniques. Computational methods help provide a 
collection of possible molecules that could be used. Used in parallel with understanding of 
hydrogen and intermolecular bonding, one can come up with a comprehensive list of drug-
approved excipients that would be examined. The next step is to run experiments (e.g. 
solvent evaporation, grinding, melting, etc.) that will hopefully result in formation of a 
novel compound. In this thesis, three poorly water soluble APIs (i.e. esomeprazole 
magnesium, curcumin and rufinamide) are investigated and screened for a solid state with 
increased solubility. Solvent-based and mechanical techniques are employed for the 
screening of novel solid states (i.e. eutectics, co-crystals, co-amorphous mixtures and 
solvates) of these APIs, and the results of these screenings are given in the succeeding 
chapters. 
1.1 Objectives 
Esomeprazole magnesium, curcumin and rufinamide are all considered to have low 
solubility in water. The main questions addressed in this thesis are: 
1. How can the crystal structure of an API be engineered to form solid states that will 
increase thermodynamic equilibrium solubility or kinetic dissolution rate? 
2. What methods can be employed to produce these novel solid states? 
3. Once formed, how will these solid states be characterized? 
1.2 Motivation 
The applications for low solubility APIs can be greatly increased if this undesirable 
characteristic were to be improved. Since higher solubility leads to greater bioavailability 
and consequently less cost due to lower dosages, the formation of novel solid states is an 
attractive approach for industry. Also, due to patent laws, pharmaceutical companies are 
constantly looking for unique forms of name brand drugs that are patented by other 
companies so that they can also produce them. Incorporating a new molecule that disrupts 
the lattice of a drug is considered innovative enough to possess its own patent, allowing 
the pharmaceutical company the ability to legally produce and sell this form of the drug. 
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Production of this new solid state is often done at a much lower overall cost than if the 
company were to invent the drug from the beginning stages. For instance, if a novel solid 
state is formed with an excipient or solvent that is already approved by the FDA, then all-
inclusive clinical testing (i.e. that for a novel drug) does not need to be conducted since the 
therapeutic effects of the API are already known. Not only does this save money, but it will 
also save the company a lot of time. These techniques are especially helpful for companies 
that create generic drugs that tend to be sold at a much lower cost.  
1.3 Background 
1.3.1 Esomeprazole Magnesium 
In 2004-2005 alone, $52,235,910 was spent by the Canadian health care system on patients 
with a primary diagnosis of esophagus related diseases, including gastroesophageal reflux 
disease (GERD).1 GERD often causes chronic heartburn, which can lead to degradation of 
the lining in the esophagus. Many of the symptoms related to GERD (i.e. those listed in 
Table 1.1) can be avoided if the disease is treated early enough by the use of a proton pump 
inhibitor (PPI).2 A very common and effective PPI is omeprazole. 
Table 1.1: Some symptoms and complications of GERD.2 
Common Uncommon Complications 
Heartburn Hoarseness and sore throat Erosive esophagitis 
Regurgitation Difficulties swallowing Esophageal stricture 
Sleep Disturbance Asthma and sinusitis Ulceration and bleeding 
Early Satiety Vomiting Esophageal cancer  
Upper abdominal 
distension  
Nausea Upper respiratory 
complaints 
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Esomeprazole (Figure 1.2 (b)), the (S)-isomer of omeprazole, was the first isolated single 
isomer PPI.3 It is currently marketed by AstraZeneca as the trihydrate form of the 
magnesium salt under the name Nexium (Figure 1.2 (a)). When compared to other PPIs 
(i.e. lansoprazole, pantoprazole, omeprazole and rabeprazole), esomeprazole was found to 
provide more effective control of gastric acid at the standard dose of 40 mg/day.4 However, 
it is considered only slightly soluble in water. 
 
The synthesis of esomeprazole on a large scale involves asymmetric oxidation of the same 
intermediate in the synthesis of omeprazole. Once coordinated to the Mg center, 
esomeprazole magnesium is found to contain only the (S)-isomer. The scheme, starting 
from the intermediate, is given in Figure 1.3.5 
 
Figure 1.3: Synthesis for large scale production of esomeprazole magnesium that 
results in sole presence of (S)-isomer of omeprazole. 
Nexium 
(a) (b) 
Figure 1.2: (a) Nexium, the marketed version of esomeprazole magnesium and (b) 
the structure of esomeprazole. 
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1.3.2 Curcumin 
Turmeric, or curcuma longa, is a root belonging to the ginger family and is very common 
in Asian cuisine (Figure 1.4 (a)). The principal curcuminiod found in turmeric is curcumin; 
though, desmethoxycurcumin, bis-desmethoxycurcumin and cyclic curcumin are also 
present. Curcuminoids are very yellow in appearance due to the polyphenols and can be 
orange if there is conjugation in the chain, which is illustrated by curcumin in Figure 1.4 
(b).6 Curcumin is a tautomer and is also present in a diketo form, but the ketol-enol 
tautomer shown below is found to be more stable and is also more effective as a drug.7   
 
 
 
 
 
 
 
 
 
 
Curcuminoids make up only 2-9% of the turmeric root, so the extraction process is critical. 
Curcumin can be extracted from turmeric via many different processes, such as solvent 
extraction, Soxhlet extraction, microwave extraction, ultrasonic extraction, use of 
supercritical CO2, etc. followed by column chromatography. The most frequently 
employed method is the use of solvent extraction with ethanol (EtOH) due to its capacity 
to be used in food and pharmaceutical processes as well as curcumin’s high solubility in 
(a) 
(b) 
Figure 1.4: (a) Curcuma longa, also known as turmeric root, is a common 
spice used in Asian cooking and (b) the chemical structure of curcumin, the 
principle curcuminoid found in turmeric, in the stable ketol-enol form. 
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EtOH. In regions where turmeric is not grown in abundance, a more viable method is to 
synthesize it. A simple synthesis route is given in Figure 1.5 that has been adopted by 
many.8 This method generally involves reacting 2,4-diketos with substituted aromatic 
aldehydes. Boron trioxide is employed to form a complex that prevents the keto groups 
from partaking in condensation reactions. The primary amine is used as a catalyst, while 
alkyl borate is a water scavenger to increase curcumin yields. Hydrochloric acid (HCl) is 
the last step to dissociate the boron complex.9 
 
Figure 1.5: General synthesis route of curcumin that is widely used. 
Curcumin extract has been shown to have many different uses and valuable health effects. 
Some of these include antioxidant10 and anti-inflammatory effects11, use as a colorimetric 
sensor12, tumor reducer13, prevention of type 2 diabetes14, etc. Many Asian countries, 
especially India, see the benefits of using turmeric since it is usually cooked in oil, which 
acts as a solvent to dissolve curcumin and allows for better uptake. Turmeric is not as 
common in Western countries, and some are not accustomed to the taste. This often leads 
to curcumin being taken in pill form, which greatly decreases the bioavailability.15 If the 
solubility of this drug could be increased, then its use in various distinct applications would 
be much more feasible.    
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1.3.3 Rufinamide 
Lennox-Gastaut is a catastrophic form of child epilepsy that has its onset from 1-7 years of 
age and tends to continue into adulthood. This syndrome and the impact of its seizures 
requires a group of health professionals to support the child and the family.16 Though first 
discovered in the 1930s, Lennox-Gastaut syndrome was later defined as a very severe form 
of childhood epilepsy characterized by frequent and multiple types of seizures, mental 
retardation and slow spike-wave electroencephalographic (EEG) patterns.17 Common 
drugs that are used to treat these seizures include clobazam, lamotrigine, rufinamide, 
topiramate and valproate.  
Rufinamide, marketed as Banzel by Eisai Co., is a triazole derivative with low aqueous 
solubility. It is produced as both a tablet and oral solution (Figure 1.6 (a)). The chemical 
structure is shown in Figure 1.6 (b); there is a lot of potential for intermolecular interactions 
with rufinamide due to the amide group, aromatic fluorine and lone pair electrons of the 
triazole ring. This leads to the investigation of possible novel solid states (such as those in 
Figure 1.1) that is described in Chapter 5. 
 
Figure 1.6: (a) Banzel in tablet form (200 or 400 mg) or oral solution, and (b) chemical 
structure of Rufinamide. 21 
Rufinamide is generally synthesized through one of the three routes depicted in Figure 1.7. 
To construct the triazole core, all three routes employ 1,3-dipolar Huisgen cycloaddition 
(a) (b) 
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of 2,6-difluorobenzylazide with a dipolarophile. Route (c) is commonly used as it uses low 
cost starting materials, does not require catalyst and can be produced continuously. 
Rufinamide can also be synthesized using continuous flow copper tubing reactor-catalyzed 
cycloaddition reaction.18 
 
 
Figure 1.7: Synthesis routes for rufinamide where schemes (a), (b) and (c) employ (E)-
methyl 3-methoxyacrylate, propiolic acids/esters and 2- chloroacrylonitrile, 
respectively. Routes (b) and (c) rely on amidation in the final step, while route (a) uses 
hydrolysis.18–20  
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1.4 Thesis Outline 
Chapter one provides a brief introduction to the low solubility APIs addressed in this thesis. 
The objectives and motivations of the work in this thesis are also given. 
A literature review of solid state formation by excipient addition is presented in chapter 
two. The subject matter included is the formation and characterization of co-amorphous 
mixtures, co-crystals, eutectics and solvates. 
In chapter three, a novel esomeprazole magnesium solvate with water and 1-butanol is 
described. The molecular structure shows how esomeprazole co-ordinates to magnesium 
for the first time. Full characterization is given.  
Chapter four presents the research conducted on curcumin, including the formation of a 
novel co-amorphous mixture with folic acid dihydrate that displays increased dissolution 
rate and has potential as a prenatal drug. Work on solid state screening and formation of 
form II is also available.  
Chapter five highlights the screening conducted with rufinamide. While no novel solid 
states were presented in this chapter, the molecular structure of modification B is illustrated 
along with a unique method to produce this metastable form. 
The final portion, chapter six, gives a conclusion on the entire thesis and provides 
recommendations for future works. 
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Chapter 2  
2 A Review of Crystal Engineering via Non-Ionic Excipient 
Addition to Increase Drug Solubility and Bioavailability  
Approximately 75% of the drugs that are being approved for use in the pharmaceutical 
industry have low aqueous solubility. This leads to issues with drug uptake, higher doses 
and consequently a negative environmental impact. One approach to improving these 
active pharmaceutical ingredients (APIs) is to use the crystal engineering technique of 
adding another molecule that disrupts the crystal lattice of the API. This method relies on 
the knowledge of the intermolecular bonds that the API can form with the excipient and 
employs many different synthesis techniques. The formation of a novel solid state is 
dependent on the strength of the intermolecular bonds formed and the type of synthesis 
used. Main synthesis routes include a variety of solution crystallization procedures as well 
as liquid assisted or neat grinding. This review will emphasize the formation of new states 
by incorporating a distinct molecule through non-ionic bonding with the API. For this 
reason, polymorphs and salts will be disregarded and the main forms analyzed are co-
amorphous materials, co-crystals, eutectics and solvates. Once formed, the proper 
characterization procedure and the methods of distinguishing these solid forms are 
discussed. Appropriate choice of excipient as well as screening methods are also given in 
detail.  
2.1 Introduction 
Every year the Food and Drug Administration (FDA) approves new molecular entities 
(NMEs) for pharmaceutical use; as of May 2017, there have already been 20 active 
pharmaceutical ingredients (APIs) accepted, this year. A biopharmaceutics classification 
system (BCS), depicted in Figure 2.1 is used by the FDA to classify APIs and reduce 
unnecessary human testing.1 The BSC goes as follows: Class I (high permeability, high 
solubility); Class II (high permeability, low solubility); Class III (low permeability, high 
solubility); and Class IV (low permeability, low solubility).2 When combined with 
dissolution studies, a biowaiver for in vivo bioavailability and bioequivalence can be 
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applied for Class I and III drugs, which leads to a less vigorous testing required for these 
drugs.3   
A simple solution to help pharmaceutical companies with more efficient drug testing (i.e. 
less clinical testing) would be to stop using drugs that do not belong to Class I and III; 
however, approximately 75% of NMEs belong to BCS Class II and IV.4 This means that 
majority of effective medicines that are FDA approved drug innovations have a poor 
solubility in aqueous solutions. Many drugs today are designed using high throughput 
screening approaches to ensure valuable and successful products. Since the approval 
process for NMEs takes years, pharmaceutical companies want to guarantee that they have 
the best contenders. The screening processes tend to result in APIs that are higher in 
molecular weight and have increased hydrogen-bonding.5 Increased molecular size results 
in greater van der Waals interaction between like molecules, while more hydrogen bonding 
within the API creates a stronger crystal lattice. Both characteristics lead to a compound 
that is more difficult to dissolve. 
Why are low solubility drugs undesirable? First, they often require high doses to reach 
required therapeutic plasma concentrations after oral administration, hence patients are 
ingesting significantly more than necessary. The increase in dose also leads to more costly 
Figure 2.1: BCS used by the FDA where highly soluble is considered when the 
highest dose strength is soluble in less than 250 mL water over a pH range of 1 to 
7.5, and highly permeable is considered when the extent of absorption in humans 
is determined to be greater than 90% of an administered dose.1 
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medicines, which is unfavourable to consumers and pharmaceutical companies. Poorly 
soluble APIs are also more vulnerable to food effects (e.g. some drugs are suggested to be 
taken after a fasting period due to reduced absorption in the presence of food), and slow 
dissolution can lead to lesser fraction absorbed in the small intestine.6 High levels of API 
excretion due to low absorption are costly to the pharmaceutical industry and can be 
detrimental to our environment. For instance, carbamezapine, a routine API that is nearly 
insoluble in water, was found in every sample taken from wastewater treatment plants’ 
effluent of three different rivers in England.7 Therefore, not only are Class II and IV drugs 
more expensive to administer, they also have a lasting effect on the Earth. Taking these 
factors into account, a strong need to increase the solubility of these drugs is prevalent. 
Crystal engineering is defined as: the understanding of intermolecular interactions in the 
context of crystal packing and the utilization of such understanding in the design of new 
solid forms with desired physical and chemical properties.8 Numerous methods are present 
that involve altering the solid state of Class II and IV APIs to increase water solubility and 
bioavailability. This altering of states is known as crystal engineering, and some of these 
approaches include formation of: salt, co-crystal, solvate, eutectic and co-amorphous 
mixture. The bioavailability of a drug is affected by its aqueous solubility, dissolution rate, 
permeability, etc. If one can increase the water solubility of Class II drugs, the 
bioavailability will be greatly improved.9 
In this chapter, the practices discussed will focus on non-ionic bonding between distinct 
molecules, so salts and polymorphs will be overlooked. The techniques mentioned involve 
adding another component called an excipient into the crystal structure; excipients will 
usually have more ideal physical and chemical characteristics than the API, so the 
combination will lead to a superior drug product. The beauty of these methods relies on the 
fact that excipients are already approved by the FDA for use in pharmaceuticals, and thus, 
the novel solid state of the API will not need to undergo new clinical studies.  
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2.2 Co-amorphous Mixtures 
An amorphous solid, also referred to as a glass, has no long range molecular order of 
packing nor does it have a distinct molecular conformation.10 Amorphous materials have 
properties similar to liquids at a molecular level but are more like solids at a macroscopic 
level.11 Due to the lack of order and since this form is the most energetic, amorphous 
compounds have been shown to have increased solubility in comparison to their crystalline 
counterparts.12 Consequently, this will also result in an increase in bioavailability, so the 
formation of an amorphous pharmaceutical compound is an appropriate means to tackle 
the issues with Class II and IV drugs.  
Co-amorphous solids, depicted in Figure 2.2 (c), occur when two components become 
amorphous due to interaction with one another. Intermolecular bonding between API and 
excipient impedes the arrangement of individual molecules into separate lattices and results 
in an amorphous material.13 Co-amorphous mixtures are shown to be not only high in 
solubility, but have a high stability.14 By adding another component into the system, the 
problem of low stability in amorphous materials is alleviated in co-amorphous materials. 
Amino acids are great candidates as excipients in these systems.15 
 
 
 
 
 
 
 
 
Figure 2.2: Representation of (a) crystalline API (green) and 
excipient (yellow), (b) amorphous API, and (c) co-amorphous 
API and excipient. 
(b)(a) (c)
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An amorphous phase composed of a single material can be created through two main routes 
of production: either a thermodynamic or kinetic disordering processes. Thermodynamic 
disordering occurs when the loss of long range order symmetry causes disorder in the solid 
state. It allows for close random packing and is termed thermodynamic disorder due to the 
breaking of symmetry.16 Kinetic disordering is referred to when long range disorder is 
caused by short range order. This process is considered to be continuous and can reduce 
crystalline material to glassy material.17 When creating an amorphous state, the 
thermodynamic pathway involves starting with a thermodynamically stable non-crystalline 
form, such as a melt or solution. The melt will then undergo quenching, while the drug will 
be precipitated from solution. Conversely, the kinetic pathway will start with a solid state 
which is then converted by introducing crystal defects via crushing, milling and continuous 
shear forces.18 These pathways are also applicable to the synthesis of co-amorphous 
systems.  
While still quite a new practice in drug formulations, co-amorphous mixtures have been 
shown to be readily obtained by a variety of procedures. The main procedures are milling 
and grinding (kinetic disordering) or quenching and solvent evaporation (thermodynamic 
disordering). Given in Table 2.1 are some instances of co-amorphous mixtures and the 
methods used to produce them. These are all desirable techniques because not only are they 
quick to produce, they also only require a small amount of sample; however, not every 
technique is applicable to every drug-excipient combination. Quenching is not available if 
degradation occurs at higher temperature, solvent evaporation can prove difficult if there 
are solubility differences, and milling may not apply enough force to disrupt the lattice.  
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Table 2.1: Preparation of Co-amorphous Systems. 
Drug Excipient 
(or drug) 
Technique Experimental 
Curcumin Artemisinin Solvent 
Evaporation 
A mixture of 1:1 molar ratio of curcumin and 
artemisinin was dissolved in ethanol. The solution was 
then rotovaped (fast evaporation under vacuum) to 
give the co-amorphous product.19  
β-azelnidipine Maleic 
Acid 
Grinding 
(LAG or neat) 
β-azelnidipine and maleic acid at molar ratios of 1:1 
and 1:2 were placed into a 50 mL stainless steel jar and 
milled at 30 Hz in a laboratory-scale oscillatory disk 
mill. This can be done neat or with the addition of 
ethanol.20  
Indomethacin Cimetidine Quenching Indomethacin–cimetidine physical mixtures were 
melted on an aluminium foil placed on a preheated 
hotplate (180°C) for 1 min. The molten liquid was 
cooled quickly by placing the aluminum foil over ice 
water.21 
 
To classify a material as amorphous, perhaps the most effective method is to use powder 
X-ray diffraction (PXRD). Crystalline material will show very distinct and sharp peaks, 
while amorphous material will appear as one very broad peak termed a halo since it has no 
defined crystal lattice or symmetry operators. To further examine the characterization of a 
co-amorphous system, the first example in  Table 2.1 will be considered. Curcumin, a 
poorly water soluble molecule, has been shown to help increase anti-malaria effects when 
taken in parallel with the API, artemisinin. Instead of prescribing these and taking them 
separately, a co-amorphous mixture was formed via fast solvent evaporation so that a 
patient could take them together. The PXRD patterns of the starting materials and the 
mixture are shown in Figure 2.3.19 It is clear that the mixture has lost the crystalline nature 
of the starting materials and is now forming weak intermolecular interactions.  
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Depending on the method used for producing the co-amorphous mixture, obtaining an 
amorphous pattern from PXRD is sufficient for characterization. If prepared via grinding, 
then the product is usually co-amorphous; however, quenching may lead to degradation 
and solvent evaporation could lead to a single amorphous state precipitating out first. To 
ensure that both starting materials are present in the amorphous product, one should 
perform solution 1H NMR (nuclear magnetic resonance). If the shifts seen are solely 
representative of both starting materials, then the product can be said to be co-amorphous. 
Keeping with the curcumin-artemisinin mixture, it was exhibited that chemical shifts for 
both starting materials were present in their product.  
Solid state NMR (ssNMR) is another method that can be used for the characterization of 
these systems. ssNMR will usually show broader bands for amorphous material compared 
to crystalline material due to the increase of molecular orientations.22 There will also be a 
shift in peaks due to the intermolecular bonding between the drug and excipient.23 
Furthermore, when compared to the ssNMR spectrum of a purely crystalline homogeneous 
mixture of the starting materials, the amorphous content of the co-amorphous system can 
Figure 2.3: The PXRD patterns of crystalline curcumin 
form I (blue), co-amorphous curcumin-artemisinin 
(purple), and crystalline artemisinin form I (pink).19 
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be determined.24 However, this technique often relies on peak integration, which can prove 
to be difficult when there is an overlap (i.e. broad peaks in amorphous materials often result 
in overlap). Also, formation of the homogeneous mixture could result in decreased 
crystallinity that would introduce error. Another method is to compare with both the fully 
crystalline and fully amorphous spectra of the starting materials. This method uses 
principal components analysis (PCA) of ssNMR data that is normalized by dividing all 
PCA scores by the score of the 100% amorphous sample after subtracting the score of the 
crystalline sample. The profile for rate of co-amorphization can be obtained by plotting the 
normalized data against mill time.25 
For further characterization, Raman and FT-IR (Fourier Transform Infrared Spectroscopy) 
can be conducted. For both techniques, the spectra will appear as a combination of the 
starting materials with small shifts in frequencies.26 The peaks that have shifted when 
compared to the starting materials, are representative of the bonds involved in the 
intermolecular bonding that stabilizes and causes formation of co-amorphous mixtures.27,28 
When coupled with ssNMR, these characterization techniques are useful in proposing a 
bonding mechanism between components of the system. Following the ongoing example, 
the proposed bonding mechanism of curcumin and artemisinin in Figure 2.4 was 
determined by analyzing the FT-IR spectrum, which showed a shift in carbonyl stretching 
of artemisinin and the phenolic alcohol of curcumin.  
 
 
 
 
Figure 2.4: Proposed bonding mechanism in the co-amorphous 
system of curcumin-artemisinin.19 
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Fundamental thermal analysis of these systems is done by differential scanning calorimetry 
(DSC). Amorphous materials will undergo a glass transition at a specified temperature (Tg), 
above which the material will tend to crystallize.29 The DSC data of a co-amorphous system 
will vastly differ from that of the starting materials. Once again considering the Curcumin-
artemisinin system, the differences can be appreciated in Figure 2.5. The melting of the 
starting materials is seen in the endothermic peaks, while the co-amorphous system has a 
broad exotherm. The Tg is highlighted and appears below the melting of both curcumin and 
artemisinin. When plotting a phase diagram of a binary system using DSC, a “v” shape 
may appear for co-amorphous mixtures with a single thermal event happening at a 
particular molar ratio.30 Since co-amorphous systems are not well studied, using DSC alone 
is not useful as its results are not universal (e.g. the formation of a “v” in the binary phase 
diagram is an ideal situation). 
 
 
 
 
 
 
 
Since amorphous materials are not crystalline, single crystal XRD cannot be obtained.  
2.3 Co-Crystals 
Much like co-amorphous systems, a co-crystal is composed of neutral, solid components 
that interact with each other through intermolecular bonding. A simple depiction of a 1:1 
molar ratio co-crystal comprised of two different compounds is given in Figure 2.6. In this 
Figure 2.5: DSC thermographs of curcumin (black), amorphous 
curcumin (red), co-amorphous curcumin-artemisinin system (blue) and 
artemisinin (green). Circled are the glass transition temperatures. 
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representation, the green component can be the API, while the orange is the excipient. 
Intriguingly, one of the components can be comprised of a salt or hydrate so long as each 
component is considered overall  neutral.31,32 Co-crystals have been known for some time 
by different names (e.g. addition compounds, mixed binary molecular crystals, molecular 
complexes, solid-state complexes, heteromolecular crystals, etc.), but have not been of 
great interest until recently. 33 To avoid being ambiguous between solid states, the FDA 
gave the following definition to co-crystals: solids that are crystalline materials composed 
of two or more molecules in the same crystal lattice.34 In a pharmaceutical co-crystal, at 
least one of these components will be an API; the excipient is referred to as the co-crystal 
former or co-former.35  
 
 
 
 
 
 
Co-crystallization occurs when an excipient is introduced that competes with and 
supersedes the intermolecular bonding of a molecule with itself.36 The most difficult task 
in co-crystal formation is picking an appropriate co-former, which will be discussed later 
on. The main intermolecular force behind co-crystal formation is hydrogen bonding, so the 
co-former should have appropriate hydrogen bond donors (HBD) and acceptors (HBA). 
There are additional contributing factors to co-crystal formation, and a statistical review of 
co-crystals in the CSD (Crystal Structure Database) leads to some general assumptions: 
co-crystals form between molecules of similar shape and polarity, and the number of 
HBD/HBA is less important than the strength of the potential hydrogen bonding.37 For 
instance, if an API has multiple functional groups and one is carboxylic, it will tend to have 
greater potential forming a co-crystal with an excipient containing an amide than with an 
Figure 2.6: Representation of a two-component 
co-crystal in a 1:1 molar ratio, where both green 
and orange represent a solid, neutral component. 
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excipient that can form multiple weaker bonds. Furthermore, if an API shows potential for 
intermolecular bonding with an excipient due to matching the HBD and HBA groups, a co-
crystal may not form if the shapes do no match (e.g. planar molecules will tend to form co-
crystals with planar molecules).  
The formation pathways for co-crystallization are comparable to those for co-amorphous 
mixtures and include liquid assisted (LAG) or dry/neat grinding, solvent evaporation, 
isothermal slurry conversion, cooling crystallization, anti-solvent crystallization, spray 
drying and rapid expansion of supercritical fluids. Provided in Table 2.2 is a summary 
which highlights examples of each method.  
Table 2.2: Some Preparation Techniques for Co-Crystal Synthesis. 
Drug Co-former  Technique Experimental 
Theophylline Citric Acid Neat 
Grinding 
0.150 g of an equimolar combination of theophylline and 
citric acid was placed into a 25 mL stainless steel 
grinding jar and ground for 1 h using two stainless steel 
balls 7 mm in diameter. The overall temperature of the 
reaction mixture remained below 35 °C.38 
Adefovir 
Dipivoxil 
Glutaric Acid LAG 1:1 mole ratio of adefovir dipivoxil and glutaric acid was 
ground using an agate mortar and pestle for 20–30 min. 
Methanol was added dropwise over the course of 
grinding (0.5 mL/mmol cocrystal).39 
Fenofibrate Nicotinamide Solvent 
Evaporation 
A mixture of FNO and nicotinamide in 1:1 molar ratio 
was dissolved in 20 mL of ethanol with sonication (to 
induce saturation) and was kept overnight to evaporate 
solvent. The crystals obtained after evaporation of 
ethanol were dried in air.40 
Trospium 
Chloride 
Salicylic 
Acid 
Quenching A 1:1 physical mixture of trospium chloride with 
salicylic acid was prepared and heated at 10°C per min 
under nitrogen purge above eutectic temperature. The 
mixture was then cooled to room temperature at a 
cooling rate of 10°C per min. After the mixture stood at 
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30°C for 60 min, the heating was repeated and the co-
crystal was obtained.41 
Indomethacin Saccharin Anti-solvent 
Addition 
In a 1L double jacketed reactor, predetermined amounts 
of indomethacin and saccharin were fully dissolved in 
methanol (300 mL), and 150 mL of purified water as 
anti-solvent was added to the solution using a peristaltic 
pump. The process was performed for 30 min and the 
product was filtered and dried under vacuum.42  
Theophylline Glutaric Acid Slurry 
Conversion 
Equimolar mixture of theophylline and glutaric acid 
was added into chloroform to form slurry at 50°C. This 
slurry was seeded with crystals from co-grinding of 
theophylline and glutaric acid and co-crystals formed as 
solvent evaporated.43 
Theophylline Saccharin Spray 
Drying 
A 0.9% equimolar solution of theophylline and 
saccharin in ethanol were spray dried at an inlet 
temperature of 120°C and outlet temperature of 77°C to 
give a co-crystal. The feed rate was 5 mL/min, the air 
flow was 536 L/h and the aspiration was 100%.44 
The most advantageous way to characterize a co-crystal is by growing single crystals and 
running X-ray diffraction. This technique will give the stoichiometric ratio, crystal lattice 
and intermolecular bonding of the molecular structure.45–48 Single crystal X-ray diffraction 
method alone is adequate in declaring that there is positive formation of a co-crystal. 
However, while it is the most useful, obtaining single crystals is an art, and it is not always 
possible. Since many co-crystals are formed using mechanochemical techniques, single 
crystals are often not achievable.49 Also, changing to conditions necessary to form high 
quality crystals can sometimes cause components to crystallize independently. In these 
scenarios, other techniques can be employed to characterize the suspected co-crystal.  
ssNMR is a practical characterization technique in helping elucidate the structure of the 
co-crystal formed. It has even been shown that ssNMR can be used to monitor co-crystal 
formation in situ.50 This method can be used for small amounts of sample, is non-invasive 
and can adequately analyze multiphase systems.51 Using 1D and 2D ssNMR techniques 
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can lead to the determination of the intermolecular bonding sites within the co-crystal.52 
When coupled with PXRD and density functional theory (DTF) calculations, 1D ssNMR 
can be employed to determine the molecular structure of a co-crystal. For example, a 
theophylline-nicotinamide co-crystal has been formed by LAG or slow evaporation with 
ethanol and is shown to have improved solubility and hygroscopicity than anhydrous API.53 
Characterization techniques and crystal engineering knowledge were used to interpret 
intermolecular bonding sites in the co-crystal. Next, this suggested bonding between API 
and excipient was refined using DTF method, and the 13C and 15N ssNMR spectra were 
predicted. These were then compared to the spectra that were obtained experimentally and 
validated the refined structure of the theophylline-nicotinamide co-crystal.54  
PXRD is also particularly useful; if a co-crystal is formed then the crystal lattice will 
change, resulting in a powder pattern that is distinct from the starting materials. This 
concept can be easily visualized by examining the theoretical PXRD patterns of an API, 
co-former and their corresponding co-crystal in Figure 2.7. It has also been demonstrated 
that PXRD can be utilized to help determine the purity of the co-crystal formed. This is 
done by formation of a calibration curve using known amounts of co-crystal and then 
monitoring the most intense peak in the PXRD pattern that has the least amount of 
overlapping.55 
 
 
 
 
 
 
 
Figure 2.7: Theoretical PXRD patterns of (a) API 
(b) co-former and (c) their co-crystal. 
2 
(a) 
(b) 
(c) 
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Thermal analysis is also critical in the analysis of co-crystals.56 Akin to the PXRD patterns, 
DSC thermographs will result in data that is different from the starting materials. The 
thermographs of co-crystals usually show an endothermic peak for co-crystal melting that 
is above or below the melting of the API and co-former.57 Ideally, the co-crystal will have 
a lower melting point than the API; this will result in bonds that are easier to break and 
increase the drug’s aqueous solubility.58 DSC can also be employed to prepare a phase 
diagram for the system. When plotting the onset of peak one and the peak temperature of 
peak two at varying molar ratios, the result is a sort of “w” shape.59 The region between 
the two eutectic peaks is the co-crystal forming region. This phenomenon is more suitably 
explained with the aid of an image (Figure 2.8).60 
 
 
 
 
 
 
 
Obtaining PXRD and DSC data that validates the presence of a co-crystal is sufficient in 
claiming co-crystal formation. To acquire the stoichiometric ratio, integration techniques 
of solution 1H NMR can be employed.61 For example, if a single proton in the API is 
normalized to one and a chemical shift representing three protons in the excipient integrates 
to three, then the co-crystal ratio is 1:1 API:co-former. If single crystal XRD and/or ssNMR 
have been attained, then Raman and FT-IR are not necessary. However, if not attained, 
these techniques will show a change in stretching frequencies which will imply that certain 
bonds are involved in intermolecular bonding and help to determine what supramolecular 
synthons (see Section 2.5) are being formed.62,63 DSC can be coupled with FT-IR as a very 
quick and easy means of co-crystal confirmation. By comparing the changes in IR 
Co-crystal forming region 
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Figure 2.8: Theoretical phase diagram of a 
binary system capable of co-crystal formation. 
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frequencies as a binary system is heated, one can confidently see where co-crystal 
formation occurs.64 Often times a combination of all or multiple techniques that have been 
mentioned are used to ensure a complete characterization so that co-crystal formation is 
irrefutable.  
2.4 Eutectics 
Like co-crystals and co-amorphous mixtures, eutectics are comprised of multiple 
components that are neutral at ambient conditions. A pharmaceutical eutectic mixture is 
comprised of API(s) and excipient(s) that do not interact to form a novel compound, but 
will impede the crystallization of each other at certain molar ratios.65 These interactions 
are short ordered and are not seen over a long range.66 Formation of eutectic mixtures is a 
useful method for weakening the intermolecular bonding of a crystalline material. This will 
reduce the melting point of a system, which will ultimately increase the solubility. The 
solubility is also increased due to the reduction in particle size (and consequently the 
increase in surface area) found in eutectics compared to the separate crystalline 
components.67 Figure 2.9 is a visualization to help comprehend the concept of eutectics: if 
the green and purple characters shown in (a) are representative of the crystal structures of 
API and excipient, then (b) and (c) are ways in which they can interact. These different 
types of interactions will be found discontinuously within the eutectic mixture and can 
interact with each other.68 The components of a eutectic mixture are miscible in the liquid 
state, but only slightly in solid state. At a eutectic composition, the API and excipient will 
crystallize out at the same time, while at any other molecular ratio one component will start 
to crystallize distinctly.69 
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The synthesis of eutectic mixtures is comparable to that of other solid states. Usually the 
same techniques are employed and will simply result in a eutectic instead of a co-crystal 
or co-amorphous mixture due to the strength of the interactions between API and excipient. 
The most common techniques include melting, grinding and solvent evaporation; some 
examples are displayed in Table 2.3. 
Table 2.3: Cases Representing Some Synthesis Techniques of Eutectic Mixtures. 
Drug Excipient 
(or drug) 
Technique Experimental 
Curcumin Nicotinamide Grinding Curcumin and nicotinamide were taken in a 
stoichiometric ratio and subjected to solid-state 
grinding in a mortar-pestle for 15 min.70 
Acetaminophen Caffeine Melting A stoichiometric mixture of acetaminophen and 
caffeine was heated to a temperature 2°C above 
complete fusion of both compounds. The mixture was 
stirred, cooled to room temperature and gently ground 
(using a mortar and pestle).71 
Aspirin Paracetamol Solvent 
Evaporation 
A different proportion of aspirin and paracetamol was 
dissolved in a methanol:dichloromethane (3:1) solution; 
the solvent was evaporated rapidly under vacuum.72 
Figure 2.9: (a) molecular structures of API (green) and excipient (purple), (b) and (c) are 
both examples of discontinuous interaction between API and excipient found in eutectic 
mixtures. These interactions can interact with each other throughout the mixture.68 
(b)(a) (c)
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Eutectic mixtures are an emblematic product when screening for pharmaceutical co-
crystals; consequently, the same techniques are employed for characterization. The initial 
step is typically to run PXRD due to its capacity for rapid analysis. The PXRD pattern for 
a eutectic mixture differs from that of co-crystals and co-amorphous mixtures since they 
are characterized by a pattern that is a combination of the starting materials (similar to a 
physical mixture) as opposed to one that is unique.73 This distinguishing characteristic is 
due to API and excipient retaining their molecular structures while still comprising of 
intermolecular bonding.  
Obtaining a PXRD pattern of this nature is not sufficient for eutectic confirmation as it may 
simply be a physical mixture of the components; the next step in characterization would be 
DSC. The thermograph for a eutectic mixture will usually appear as a melting endotherm 
that occurs at a temperature below both API and excipient melting.74 A physical mixture 
differs and will show two distinct melting points, since the constituents are not 
interacting.75 At a specific ratio, this endotherm will appear as a single peak resembling a 
co-crystal; however, since the PXRD pattern is not distinct, it is known to be a eutectic and 
no exothermic events will occur.59 Running DSC at different molar ratios and plotting the 
binary phase diagram (as previously described) will result in a graph that has a “v” shape 
similar to Figure 2.10.  
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binary system which forms a eutectic. 
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These two techniques, PXRD and DSC, are typically sufficient in determining if a eutectic 
has formed. Solution 1H NMR can be run to confirm stoichiometric ratios. FT-IR, Raman 
and ssNMR will all mirror PXRD in terms of obtaining result that reflect a combination of 
the starting materials.70 Confocal Raman Microscopy has been employed to show 
discontinuous bonding in eutectic mixtures by monitoring characteristic bonding peaks.76 
2.5 Solvates 
Contrary to the previous solid states that have been discussed and consist exclusively of 
solid materials at room temperature, a solvate is comprised of multiple components where 
solvent(s) has been incorporated into the crystal lattice.77 A special case, termed a hydrate, 
occurs when solvent involved is water.78 Liquid solvent at ambient conditions can be found 
in both stoichiometric and non-stoichiometric amounts, as depicted in Figure 2.11.79 A 
solvate is described simply as any crystal composed of a solvent molecule and either a co-
former or a cation-anion pair (Figure 2.11(c)). When the components are found in 
stoichiometric amounts, this is referred to as a “true solvate” (Figure 2.11(b)).80  
 
 
 
 
 
 
 
Pharmaceutical solvates will contain an API as a co-former or pharmaceutical salt as the 
cation-anion pair. Solvent can incorporate into the voids of the crystal lattice and is 
recognized as channel solvent.81 These types of solvates will retain their crystal structure 
(b)(a) (c)
Figure 2.11: Representation of (a) crystalline API (green) and solvent 
(blue), (b) stoichiometric or ‘true” solvate, and (c) non-stoichiometric 
solvate. 
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if the solvent is removed and can be found in stoichiometric or non-stoichiometric 
amounts.82 Another type involves stronger intermolecular bonding between the solvent and 
the solid that results in a distinct and more stable crystal lattice. In this scenario, 
functionality is a more vital factor in solvent inclusion.83 The extent of stabilizing, 
intermolecular bonding found in these solvates includes: hydrogen bonding, halogen 
binding, metallic bonding and Van der Waals Interactions.84,85 
Since solvent (especially water) is present in many stages of pharmaceutical production, 
solvates are an interesting means of increasing the solubility and stability of drugs. Water 
and many other solvents have potential to form strong hydrogen bonding interactions with 
a variety of molecules that could result in the formation of a crystal lattice with increased 
stability.  Removing solvent can lead to the decomposition of the API or ruin its crystal 
lattice.86 Instead of trying to remove solvent from the system as waste, alternatively, it can 
be incorporated (so long as it is safe for ingestion).  
Synthesis of solvates is usually achieved via cooling and/or evaporative crystallization 
from solution. Both methods rely on supersaturation to promote crystal growth. Solvates 
have also been formed via grinding.87 A case for the synthesis of each type of solvate is 
given in Table 2.4. 
Table 2.4: Cases Representing the Synthesis of Different Types of Solvate Systems. 
Drug Solvent Solvate Type Experimental 
Atorvastatin 
 
Isopropanol Stoichiometric 
Channel 
Atorvastatin was stirred in acetone and 
isopropanol just below boiling point for over 24 
hours. The solution was filtered, water added as 
anti-solvent and the product is allowed to 
crystallize in air at room temperature.88  
Sitagliptin L-
tartrate 
Water Non-stoichiometric 
Channel 
Solvate was crystallized from a 2-propanol:water 
(8:2, v/v) mixture in air at room temperature.89 
Dirithromycin Cyclohexane Stoichiometric 
Lattice Inclusion 
Solvate isolated by vapor diffusion of cyclohexane 
into a toluene solution of Dirithromycin.90 
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After a solvate has been formed, one needs to properly characterize it. Once again, single 
crystal XRD is the all-telling technique for characterization. The data obtained will result 
in the molecular structure which can be used to establish the intermolecular bonding 
between components, whether a “true solvate” has been formed, if the solvent is located 
predominantly in the voids, and much more. To explore this method, an Esomeprazole 
Magnesium solvate, displayed in Figure 2.12 and discussed in detail in Chapter 3, will be 
investigated. Esomeprazole Magnesium is a poorly soluble pharmaceutical salt with low 
stability. In this solvate, water is bonded in two distinct modes: strong dative-covalent 
bonding directly with Mg and in the voids of the crystal lattice. The former water molecules 
are bonded more powerfully than the latter. The 1-butanol molecules are also found in the 
channels and can be seen to form hydrogen bonds with water. This compound is determined 
to be a “true solvate” with respect to the water molecules, and butanol is found in non-
stoichiometric amounts.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: Esomeprazole Magnesium solvate with 
water and 1-butanol. Hydrogen bonding between 
molecules is shown in blue.79 
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Since single crystals are not easily attainable, there are a variety of other techniques that 
can be used for characterization. PXRD is particularly useful when the solvate is 
synthesized via the formation of a new crystal lattice that incorporates the solvent. This 
will result in a PXRD pattern that is novel in comparison to the API.91 Conversely, if the 
solvent is simply filling the voids in the crystal lattice, the PXRD pattern will appear to be 
analogous to that of the API with very slight differences. In this situation, it is necessary to 
conduct further analysis, such as ssNMR, to ensure that a solvate has indeed been formed.92 
An outstanding illustration of this is seen in Figure 2.13; 13C ssNMR spectra is taken for a 
non-stoichiometric solvate where solvent is found in the channels. The solvate is then 
heated to remove solvent and the resulting spectra are observed, while PXRD patterns 
showed no differences as the solvent was removed.93  
 
 
 
 
 
 
 
 
 
Dynamic Vapor Sorption (DVS) is another valuable tool in analyzing pharmaceutical 
solvates. This instrument measures the mass of a sample with respect to changes in relative 
humidity (RH). For example, if a hydrate-forming API is put into an environment of 
increasing humidity, a change in mass is seen during hydrate formation. The additional 
mass will correspond to the ratio of water incorporated into the system, and the graph will 
Figure 2.13: 13C ssNMR of a non-stoichiometric, channel 
solvate LY297802 tartrate at (a) ambient conditions, (b) 
elevated temperature with solvent removal, and (c) 
elevated temperature with increased solvent removal.93 
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form a hysteresis, such as the one shown in Figure 2.14.94 This technique can also be used 
with other organic vapors to determine solvate formation.95 Solvates that can form in 
multiple ratios or non-stoichiometrically will show multiple hysteresis. If solvate is found 
to bind only to the surface, it is easily removed and usually appears as a linear increase in 
mass with increasing RH.96 Solvent that is incorporated into the crystal lattice will not 
instantly be removed; this is illustrated in Figure 2.14, as well. Once the solvate has formed, 
it takes a significant decrease in humidity to remove it from the lattice.97  
 
 
 
 
 
 
 
Solution NMR is not a useful technique to determine the amount of solvent present due to 
contaminations. Often the solvate is a hydrate, and water is found in many deuterated 
solvents.98 A more appropriate method is to use thermal analysis such as DSC and TGA 
(thermogravimetric analysis). DSC will show the removal of solvent as an endothermic 
peak. Due to intermolecular interactions, solvent will evaporate above its boiling point. 
Channel solvent is usually removed much easier and closer to boiling temperatures. TGA 
monitors the weight loss as a substance is heated. The percentage lost (assuming the API 
has not decomposed) will correspond to how much solvent has been removed, which can 
then be used to calculate the ratio of sovent:API.99  
Figure 2.14: Hysteresis shown for an API with the 
capability to form a solvate. Relative humidity is 
increased gradually and then reduced.94 
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2.6 Excipient Selection and Solid State Screening 
The excipient that is chosen for inclusion into a drug’s solid state should increase the 
solubility and consequently the bioavailability of the drug. This is mainly done by choosing 
molecules that are water soluble and have plenty of potential for intermolecular bonding.100 
It is also ideal to pick an excipient with a melting point lower than the API for reasons 
previously mentioned. The principal approach used in choosing an appropriate molecule is 
the supramolecular synthon method, which evaluates the potential intermolecular bonds 
between separate constituents of the multi-component solid state.101 Illustrated in Figure 
2.15 are both hetero- and homosynthons: one involving a bond that interacts with the same 
type of bond (e.g. carboxylic-carboxylic) and the latter being dissimilar bond types 
interacting with each other (e.g. carboxylic-amide). It was reported that heterosynthons are 
more energetically stable; however, homosynthons are still a feasible means of 
intermolecular bonding.102 The proposed intermolecular bonding should be strong enough 
to displace the bonding of the single components with themselves in order to synthesize 
the aforementioned solid states. 
 
 
 
 
 
A database of approved excipients is easily accessible from the FDA.103 Table 2.5 is an 
example of the results for the molecule ethylparaben (EPB). This excipient is pre-approved 
for use in drugs both orally and topically with potency varying depending on the method 
administered. If, for example, to form a co-crystal between an API and EPB, it should be 
in a ratio that will not cause EPB to be administered more than ~0.6 mg per dose.  
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Figure 2.15: Hydrogen bonding motifs of (a) carboxylic-carboxylic 
homosynthon and (b) a carboxylic-amide heterosynthon. 
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Table 2.5: Inactive Ingredient Search for Approved Drug Products, EPB 
Where CAS is Chemical Abstracts Services, UNII is Unique Ingredient Identifier and EPB is ethylparaben. 
Another source that researchers can use when choosing excipients is the Generally 
Regarded as Safe (GRAS) database, which is also published by the FDA.104 Based on 
current studies, molecules are given an evaluation from 1-5, and the meanings of these 
ratings are specified in Table 2.6. Ascorbic acid, also known as vitamin C, is given a 
conclusion of 1 since it is well studied and known to be safe for consumption. 
Conclusions 1 and 2 are acceptable excipient choices for solid state modifications. This 
database, however, can lead to some misleading results (e.g. nutmeg is listed as class 3, 
but it is ingested frequently in food). Also, since these inactive ingredients are not 
necessarily approved for use in drug products, new clinical testing may need to be 
Inactive 
Ingredient 
Route Dosage Form CAS 
Number 
UNII Maximum 
Potency 
Ethylparaben Oral Granule, For 
Oral Solution  
120478 14255EXE39 0.6 mg 
Ethylparaben Oral Powder, For 
Oral Solution 
120478 14255EXE39 0.66 mg 
Ethylparaben Oral Powder, For 
Solution 
120478 14255EXE39 0.6 mg/2 g 
Ethylparaben Oral Solution 120478 14255EXE39 0.6 mg/5 mL 
Ethylparaben Oral Suspension 120478 14255EXE39 2 mg/5 mL 
Ethylparaben Topical Emulsion, 
Cream 
120478 14255EXE39 NA 
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conducted. The preferred method for excipient choice should be the Inactive Ingredient 
Search for Approved Drug Products Database. 
Table 2.6: Types of Conclusions from the Selection Committee on GRAS Substances 
Type of 
Conclusion 
Definition 
1 There is no evidence in the available information on [substance] that demonstrates, or 
suggests reasonable grounds to suspect, a hazard to the public when they are used at 
levels that are now current or might reasonably be expected in the future. 
2 There is no evidence in the available information on [substance] that demonstrates a 
hazard to the public when it is used at levels that are now current and in the manner 
now practiced. However, it is not possible to determine, without additional data, 
whether a significant increase in consumption would constitute a dietary hazard. 
3 While no evidence in the available information on [substance] demonstrates a hazard to 
the public when it is used at levels that are now current and in the manner now 
practiced, uncertainties exist requiring that additional studies be conducted. 
4 The evidence on [substance] is insufficient to determine that the adverse effects 
reported are not deleterious to the public health should it be used at former levels and in 
the manner formerly practiced. 
5 In view of the almost complete lack of biological studies, the Select Committee has 
insufficient data upon which to evaluate the safety of [substance] as a [intended use]. 
 
 Another source for finding excipients is the Everything Added to Food in the United States 
(EAFUS) lists.105 As the name states, these lists include chemicals that the FDA has 
approved for additives in food.106 It is theorized that if the substance is safe for ingestion, 
then it can be used to some extent for oral administration.  
The databases mentioned above are suitable to use when choosing an appropriate solvent 
for solvate formation; however, perhaps a more appropriate method is to use the ICH’s 
(International Council for Harmonisation of Technical Requirements for Pharmaceuticals 
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for Human Use) guideline for residual solvents. Solvents are given a Class 1-3 where Class 
1 should be avoided for use in pharmaceutical production, 2 should be limited and 3 has 
low toxic potential. For solvate formation, one should only consider Class 3 solvents that 
have a permitted daily exposure of 50 mg or more.107 
The molecule that is added for intermolecular interaction with the API may not always be 
an inactive ingredient. Recently, drug-drug compounds have become of increasing interest; 
they have been employed to reduce number of prescriptions, reposition drugs, reduce 
production cost and increase therapeutic effect.108 It has been shown that combining 
antihypertension drugs that display poor aqueous solubility via co-crystal, co-amorphous 
mixture and eutectic formation leads to increased antihypertension activity.109 As an 
outcome, number of prescriptions and production costs should decrease. 
Now that an appropriate excipient has been chosen, which is arguably the most difficult 
task in this approach of crystal engineering, an extensive screening process must 
commence. While solid state formation procedures are well studied, they are still not 
necessarily well understood, especially in terms of which combinations will form novel 
solid states; therefore, proper screening is essential for successful crystal engineering.110 
An extremely efficient means of screening involves grinding API and potential excipient 
together at varying molar ratios and collecting the DSC thermographs at a heating rate of 
10K/min. This can only be done when there is no decomposition of the components before 
their melting.111 When done without the presence of solvent (neat grinding), this technique 
is considered “green” and does not complicate the system with possible solvate formation 
such as with LAG.112 If the resulting phase diagram gives a “w” shape, then co-crystal 
formation is possible; if a “v” shape is determined then there is likely a eutectic or co-
amorphous product. If the melting endotherms are found not to converge, then the resulting 
product is merely a physical mixture, such as the illustration in Figure 2.16.113  
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For a more rapid screening, one can merely run the DSC for ground mixtures of 1:1, 1:2 and 
2:1 molar ratios of API:excipient.114 One scenario is the presence of a melting endotherm that 
is distinct from the melting of the starting materials and is found at a consistent temperature 
in all three ratios. If the PXRD pattern shows novel peaks, then co-crystal formation is 
possible. Another scenario is the presence of an endothermic peak found lower than the 
melting temperature of the API or excipient that will alter slightly with varying molar ratio. 
Running PXRD will indicate if the product is co-amorphous or a eutectic.  
While these techniques are both effective and reliable, they are not applicable for solvate 
formation, and sometimes solvent effects promote the formation of different solid states (e.g. 
a co-crystal that can be synthesized from solution but not from LAG). Solution methods 
usually involve dissolving API (and often excipient) in solvent(s) and seeing what product is 
obtained via slow evaporation and/or cooling. Another technique is to create a 
suspension/slurry that is allowed to equilibrate at ambient conditions.115 A clear drawback is 
that crystallization may occur slowly, and solubility issues could lead to single phases 
crystallizing out. Conceivably, screening with solvent(s) should be run in parallel to the DSC 
methods mentioned, so multiple solid states can be screened simultaneously. Using solvent 
mixtures helps decrease the solubility differences between API and excipient and can promote 
co-crystal over solvate formation if low enough solvent concentrations are employed.116 
Another screening method, known as the Kofler technique, employs hot stage microscopy and 
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Figure 2.16: Binary phase diagram of an API and excipient 
incapable of forming intermolecular interactions (physical mixture). 
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is useful for solid state screening. One component is melted and allowed to solidify, then a 
second molten phase is introduced. This partially solubilizes the first component in the second 
and a mixing zone is created that contains a concentration gradient (Figure 2.17). In this 
mixing zone, a novel solid state may form under suitable conditions. Light microscope is used 
to observe the number of melting points while heating.117 One melt is relevant for co-
amorphous and eutectic mixtures, while two melts are seen for co-crystal. Co-crystal 
formation will result in a crystalline phase at the interface.118 
 
 
 
 
 
 
 
 
 
With appropriate screening and sufficient excipient/solvent selection, one can efficiently 
obtain a novel solid form that will potentially display increased solubility and bioavailability.  
Summary 
The FDA releases dozens of NMEs per year for pharmaceutical usage, and most of these drugs 
have very low aqueous solubility (i.e. the highest dose strength is soluble in more than 250 
mL water over a pH range of 1 to 7.5). The solubility of Class II and IV drugs can be improved 
through the crystal engineering technique of adding another molecule into the crystal lattice 
of the API. This molecule should be pre-approved for use in pharmaceuticals and not interact 
API Excipient 
Zone of 
Mixing 
Figure 2.17: API (higher melting point) is melted 
and recrystallized before excipient is brought 
into contact which creates a zone of mixing.117 
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with the API. Use of this type of excipient requires no clinical testing, which is very 
advantageous to industry. Potential excipients can be narrowed down using a computer-based 
software that statistically analyzes molecular complementarity of the API with a list of 
common co-formers established from their molecular structure. Another technique, called the 
molecular synthon approach, will analyze the potential intermolecular bonding of the API and 
find corresponding excipients. Once a list of excipients is chosen, they should be screened 
using solvent crystallization in parallel with grinding and DSC techniques. 
Should the screening result in the formation of a novel solid state, it is essential that it is 
appropriately identified. The first step should be to have the proper characterization of both 
the API and the excipients used; this will lead to an easy comparison and solid state analysis. 
Next, one should run PXRD on the new product. For the solid states mentioned in this review 
(i.e. co-amorphous mixtures, co-crystals, eutectics and solvates), there are three different 
outcomes from the evaluation of the PXRD patterns. If the product’s pattern shows no new 
peaks and appears as a combination of the starting materials, then the result is either a physical 
mixture or a eutectic. If there are peaks that are distinct from the starting materials (and their 
polymorphs) or an entirely new pattern is observed, then the resulting solid state could either 
be a co-crystal or solvate. The final option is to observe a “halo” in which there is simply one 
very broad peak. This pattern is characteristic of an amorphous material.  
A good idea at this point would be to run 1H NMR on the product and compare it to that of 
the starting materials. Are the chemical shifts corresponding to the API present? How about 
the shifts for the excipient or solvent? Solution NMR is a valuable tool to ensure that the API 
did not decompose and determines what is present in their product. If a PXRD pattern of the 
product resulted in novel peaks and 1H NMR revealed that the excipient (or solvent) was 
present, then the result is most likely a co-crystal (or solvate). Likewise, if the PXRD pattern 
was amorphous and both starting materials are present in the NMR spectrum, then the product 
is co-amorphous. 1H NMR cannot be used to help elucidate physical mixtures from eutectics. 
The next step would be to run thermal analysis to validate the formation of a new solid state. 
If there is a single peak in DSC that is distinct from the melting of the starting materials, then 
the product is a co-crystal. If there is a mixture of co-crystal and starting material, then three 
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peaks should be observed: one for eutectic melt, one for co-crystal melt and one for the 
melting of excess API. The melting point of the co-crystal is usually seen between the melting 
points of the starting materials. Solvates will often result in a thermograph that shows the 
evaporation of solvent in the lattice above its boiling point, followed by the melting of the 
API. TGA should be run on potential solvates to see if the weight loss corresponds to solvent 
loss. Co-amorphous mixtures are not predictable in their DSC thermographs but will often not 
show the melting of the starting materials, and an exothermic peak will be present. Physical 
mixtures will simply show the melting of each starting material in DSC, while eutectics will 
melt below the lower melting point starting material (usually excipient). DSC is also useful 
to plot phase diagrams. Eutectics and co-amorphous systems will give a “v” shape, while co-
crystals will result in a “w” shape. The melting points in physical mixtures will not converge, 
so no such shape will be present. 
These techniques are usually sufficient in determining what solid state is formed, but they can 
be aided by ssNMR, FT-IR and Raman. The ultimate tool would be to determine the molecular 
structure from single crystal XRD, but often it is difficult to grow crystals of appropriate 
quality. After a novel solid state is formed, the rate that dissolves should be determined and 
compared with that of the API through intrinsic or powder dissolution rate studies. If the novel 
product is found to have an increased solubility compared to the API, then a viable alternative 
to the API has been synthesized. The same can be said if the dissolution rate is increased, 
since the API will have only a limited time in solution (i.e. in the body). The pharmaceutical 
company can now investigate patenting and eventually distributing this form. 
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Chapter 3  
Crystallization of Esomeprazole Magnesium Water/Butanol 
Solvate 
The molecular structure of esomeprazole magnesium derivative in the solid-state is 
reported for the first time along with a simplified crystallization pathway. The structure 
was determined using single crystal X-ray diffraction technique to reveal the bonding 
relationships between esomeprazole heteroatoms and magnesium. The esomeprazole 
crystallization process was carried out in 1-butanol and water was utilized as anti-solvent. 
This compound proved to be esomeprazole magnesium tetrahydrate with two 1-butanol 
molecules that crystallized in P 63 space group, in a hexagonal unit cell. Complete 
characterization of a sample after drying was conducted by the use of powder X-ray 
diffraction (PXRD), 1H nuclear magnetic resonance spectroscopy (NMR), 
thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), infrared 
spectroscopy (IR), and dynamic vapor sorption (DVS). Investigation by 1H NMR and TGA 
has shown that the solvent content in the dried sample consists of two water molecules and 
0.3 butanol molecules per one esomeprazole magnesium molecule. This is different from 
the single crystal X-ray diffraction results and can be attributed to the loss of some water 
and 1-butanol molecules stabilized by intermolecular interactions. The title compound, 
after drying, is a true solvate in terms of water; conversely, 1-butanol fills the voids of the 
crystal lattice in non-stoichiometric amounts.  
Introduction 
Esomeprazole, the (S)-enantiomer of omeprazole, is the first single optical isomer proton 
pump inhibitor.1 This eutomer forms an active inhibitor achiral sulphenamine when in the 
acidic compartment of the parietal cell. The activated form of omeprazole prevents the 
formation of gastric acid by blocking the enzyme H+/K+-ATPase, which is accountable for 
the formulation of gastric acid and is found in the secretory membranes of the parietal cell.2 
The stability of this active pharmaceutical ingredient (API) is a function of pH and acidic 
conditions must be avoided. In acidic conditions, omeprazole can degrade to form at least 
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five distinct impurities. These degradants do not inhibit the production of gastric acid and 
reduce the competence of the pharmaceutical.3 Omeprazole has been documented to 
decompose up to 10% in air due to moisture.4 Esomeprazole has been presented in various 
forms of alkaline salts as a means of increasing stability. The salt of interest is 
esomeprazole magnesium, which has a half-life of 19 hours at 25 °C and 8 hours at 37 °C 
while at pH 6.5  
Omeprazole possesses a single stereogenic center on the sulfur atom and is by definition a 
racemic mixture of the (R) and (S) enantiomers. The (S)-enantiomer of this API is found 
in higher concentrations in plasma membrane compared to the (R)-enantiomer because it 
is more slowly and less variably metabolized. The intrinsic clearance is three times lower 
for esomeprazole, meaning longer resonance time in vivo. The active inhibitor formed is 
the same for both isomers and as a result they have the same effect on the body 6. Shown 
in Figure 0.1, esomeprazole displays tautomerism of the benzimidazole N-H hydrogen 
atom, resulting in 5-methoxy and 6-methoxy tautomers. In solution, both tautomers are 
present but the 6-methoxy derivative is favoured nearly 2:1.7 According to 1H and 13C 
NMR studies, the 6-methoxy tautomer is the only form present in the solid state.8 It has 
also been confirmed through crystallographic analysis that the 6-methoxy derivative is 
more stable.9 This combination of chirality and tautomerism allows for a wide range of 
possible crystalline structures of this API.  
 
Figure 0.1: The 5-methoxy and 6-methoxy tautomers of omeprazole. 
A potential technique to stabilize esomeprazole is to form a solvate by incorporating 
solvent molecules into the crystal lattice of the API via intermolecular forces. In a “true” 
solvate, Figure 0.2 (a), the solvent molecules become included in the unit cell in 
stoichiometric amounts. The crystal structure will collapse when solvent is removed from 
these solvates. Alternatively, solvent molecules can fill the voids and channels of the 
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crystal structure in non-stoichiometric amounts. These types of solvates, shown in Figure 
0.2 (b), will remain crystalline when solvent is removed.10 When forming a solvate, one 
must be vigilant in ensuring that the incorporated solvent is not toxic to the consumer at a 
given dosage.11 Minimal research articles have been published exploring the possibility of 
esomeprazole solvates, though a crystalline form of omeprazole sodium ethanol solvate 
has been reported.12,13 
 
Figure 0.2: A simplified visualization of (a) a “true” solvate vs (b) a non-
stoichiometric solvate, where the solvent can be one or more types of solvent. 
Analogous to many prospective APIs, the instability of esomeprazole poses concerns for 
industry in manufacturing and storage.14 Since water is present throughout many industrial 
processes, one attempt at stabilization is through the investigation of possible 
pseudopolymorphs, such as hydrates. Pharmaceutical hydrates occur when water becomes 
incorporated into the crystal lattice of an API by means of intermolecular bonding.15 The 
small size relative to most pharmaceuticals, as well as the hydrogen bonding ability of 
water, make it an ideal molecule to incorporate into the crystal lattice.16 To date, there are 
patented examples of esomeprazole magnesium in tetrahydrate, trihydrate, dihydrate, 
monohydrate and hemihydrate forms.17,18 In a study of esomeprazole magnesium hydrates, 
it was found that the stability order in water is trihydrate > dihydrate form A > tetrahydrate 
> dihydrate form B. The solubility order in water was determined to be dihydrate form B 
> tetrahydrate > dihydrate form A > trihydrate.19 
 
(a) (b) 
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Materials and Methods 
Esomeprazole magnesium (MW= 713.12 g/mol) was provided by Apotex Pharmachem 
Inc. and kept in an inert environment when in storage. 1-butanol was purchased from 
Fischer Scientific and used in crystallization. All 1H NMR spectra were obtained from 
solutions in DMSO-d6 purchased from Sigma Aldrich. 
A Bruker Apex II Diffractometer with Mo X-ray radiation was used to obtain the crystal 
structure of the title compound. Powder X-ray Diffraction was obtained from a Rigaku 
Miniflex instrument with Cu X-ray radiation. Scans were run at a speed of 1.00°/minute 
for 2θ values of 2.00-40.00°. Thermogravimetric analysis and differential scanning 
calorimetry were conducted on the Mettler-Toledo STARe 851e and 822e instruments, 
respectively, at a heating rate of 5 °C /minute from 25-350 °C. 1H NMR spectrum was 
collected on a Mercury VX 400 MHz machine. IR results were obtained over 32 scans 
from 4000 cm-1 to 500 cm-1 using a Nicolet 6700 FT-IR spectrometer. DVS-1000, from 
Surface Measurement Systems Ltd., was used to obtain results for dynamic vapor sorption. 
The esomeprazole magnesium water/butanol solvate was obtained by dissolving 0.750 g 
of amorphous esomeprazole magnesium in 7.0 mL of 1-butanol. Once in solution, it was 
filtered to obtain a clear solution, then 1.0 mL of distilled water was added and stirred until 
miscible. The solution was kept overnight at 5.0 °C. Crystalline powder was formed which 
was filtered and washed with 1-butanol. Surface solvent was removed by heating under 
vacuum at 50-55 °C for up to 16 hours. The single crystal sample was obtained by 
dissolving 0.700g of amorphous esomeprazole magnesium in 40.0 mL of 1-butanol. To the 
clear solution, 2.0 mL of distilled water was added. The solution was then left at 5.0 °C for 
2-3 weeks until single crystals had formed. 
 
Results and Discussion 
In the present work, a novel form of esomeprazole magnesium has been characterized by 
single crystal X-Ray diffraction, powder X-ray diffraction (PXRD), 1H NMR 
spectroscopy, infrared spectroscopy (IR), thermogravimetric analysis (TGA), differential 
scanning calorimetry (DSC) and dynamic vapour sorption (DVS). The trihydrate form is 
known to be soluble in methanol, ethanol and 1-butanol.20 The solubility in ethanol is low, 
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and methanol is toxic to humans. Since 1-butanol is on the FDA approved list of 
solvents/excipients, the esomeprazole magnesium water/1-butanol solvate was further 
investigated. Additionally, crystallization of this solvate was particularly simple and 
moderately short.  
Existing literature contains the single crystal structures for omeprazole and toluene 
hemisolvate piperazinium esomeprazolate.9,21,22 To better understand the bonding and 
structure of esomeprazole derivatives, various efforts were made at forming single crystals. 
Plate like single crystals were formed from a solution of amorphous esomeprazole 
magnesium in 1-butanol in the presence of water at 5 °C after approximately three weeks. 
The sample was mounted on a Mitegen polyimide micromount with a small amount of 
Paratone N oil. All X-ray measurements were made on a Bruker Kappa Axis Apex2 
diffractometer at a temperature of 110 K. The unit cell dimensions were determined from 
a symmetry constrained fit of 9907 reflections with 6.4° < 2θ < 46.62°. The data collection 
strategy was a number of ω and ϕ scans which collected data up to 51.468° (2θ). The frame 
integration was performed using SAINT.23 The resulting raw data was scaled and 
absorption corrected using a multi-scan averaging of symmetry equivalent data using 
SADABS.24 The structure was solved by using a dual space methodology using the 
SHELXT program.25 All non-hydrogen atoms were obtained from the initial solution. All 
hydrogen atoms except for water molecules were introduced at idealized positions and 
were allowed to ride on the parent atom. The hydrogen atoms on the water molecules were 
added considering hydrogen bonding with nitrogen or oxygen atoms around them. The 
structural model was fit to the data using full matrix least-squares based on F2. The 
calculated structure factors included corrections for anomalous dispersion from the usual 
tabulation. The structure was refined using the SHELXL-2014 program from the 
SHELXTL suite of crystallographic software.26 Graphic plots were produced using the 
Mercury program suite  (Summary of crystal data in Table 0.1).27 CCDC 1468173 contains 
the supplementary crystallographic data for this paper. These data can be obtained free of 
charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
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Table 0.1: Summary of Crystal Data. 
Formula C126H198Mg3N18O36S6 
Formula Weight (g/mol) 2806.30 
Crystal Dimensions (mm) 0.185 × 0.142 × 0.092 
Crystal System Hexagonal 
Space Group P 63 
Temperature, K 110 
a, Å 14.701(4) 
b, Å  14.701 
c, Å  39.123(11) 
,° 90 
,° 90 
,° 120 
V, Å3 7323(5) 
Z 2 
F(000) 3000 
 (g/cm) 1.273 
, Å, (MoK) 0.71073 
, (cm-1) 0.185 
R1 0.0674 
wR2 0.1733 
GOF 1.032 
Maximum shift/error 0.000 
Min & Max peak heights on final F Map (e-/Å) -0.497, 0.487 
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Figure 0.3: Esomeprazole magnesium molecules crystalize in P 63 spaces group 
alongside with water and 1-butanol molecules; the molecules of the same colour are 
symmetry equivalent. 
Molecules of esomeprazole magnesium crystallize in the space group P 63, with Z = 2, 
alongside four water and two 1-butanol molecules (C126H198Mg3N18O36S6) (Figure 0.3). As 
it is shown in Figure 0.4, coordination around the magnesium centers is octahedral. For 
every Mg center that has six water molecules around it, there are two magnesium centers 
that are coordinated with three esomeprazole ligands. All of the esomeprazole molecules 
act as chelating ligands and coordinate the Mg centers with one oxygen as well as one 
nitrogen atom. This agrees with previous DFT calculations, where omeprazole was shown 
to favour coordination with Co(II) and Fe(III) through the sulfoxide oxygen and the 
benzimidazolic nitrogen.28 All of the six water molecules that are coordinated to the 
magnesium center show hydrogen bonding either with other water molecules in the lattice 
or the nitrogen atoms in the esomeprazole ligands (Figure 0.5). 1-Butanol molecules fill 
the voids in this lattice and are also hydrogen bonded to the water molecules in the lattice. 
 
 
58 
 
 
Figure 0.4: Two types of coordination around the magnesium centers, hydrogen 
atoms and non-bonded solvents have been omitted for clarity. Mg: green, S: yellow, 
O: red, N: blue, C: grey. 
 
Figure 0.5: Strong hydrogen bonding between the molecules in the lattice are shown 
in blue dotted lines; hydrogen atoms have been omitted for more clarity. Mg: green, 
S: yellow, O: red, N: blue, C: grey. 
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From the single crystal structure, the powder pattern was simulated and is shown in Figure 
0.6. This pattern is different than that of the crystals which have been dried under vacuum. 
In the pattern of the dried sample, the peaks at 2θ = 7° and 8° are much lower in intensity. 
As well, the simulated peak at 2θ = 4.5° has shifted to 5.1°; however, the peak at 2θ = 18.5° 
is consistent in both simulated and experimental powder pattern. Some solvent molecules 
have been removed from the lattice, and as a result, a different polymorph according to the 
PXRD pattern is formed. This is further proved by other characterization techniques that 
are discussed below. As seen in the single crystal analysis, water is found in the channels 
of the lattice along with being bonded to the magnesium cation. The dative covalent 
bonding of water to the magnesium is much stronger than the hydrogen bonding displayed 
by the channel water molecules. The change in PXRD pattern shows that the crystal lattice 
has changed by removing some of the water and 1-butanol molecules. The pattern obtained 
of the solvate after drying is comparable to that of esomeprazole magnesium dihydrate 
form A, with equivalent peaks at 2θ = 5° and 18°.29 The X-ray pattern was consistent for 
the sample after drying under vacuum at 50 °C for two hours and up to 16 hours. The 
powder diffraction also remained the same for samples that were exposed to air. Since 
esomeprazole is known to be chemically unstable in air, the ability of the esomeprazole 
magnesium water/1-butanol solvate to remain crystalline in air highlights a potential 
advantage for its use in pharmaceutical solid dosage forms. 
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Figure 0.6: X-ray powder diffraction of esomeprazole magnesium water/butanol 
solvate calculated from single crystal structure and esomeprazole magnesium 
water/butanol solvate after drying under vacuum. 
In order to confirm the occurrence of 1-butanol in the crystal lattice after drying, 1H NMR 
data was collected from the dry sample in DMSO-d6 solution (see Appendix A, Figure A-
1). The presence of water and 1-butanol is clear by analysis of the spectrum; esomeprazole: 
1H NMR δ 8.25 (m, 1H), 7.37 (d, J=8.6 Hz, 1H), 7.02 (d, J=2.6 Hz, 1H), 6.60 (dd, J=2.5 
Hz, 8.4 Hz, 1H), 4.72 and 4.46 [d (AB system, J=12.7 Hz, 2H)], 3.75 (s, 3H), 3.70 (s, 3H) 
2.21(s, 6H); 1-butanol: 1H NMR δ 4.30 (t, 2H), 3.38 (q, 1H), 1.39 (m, 2H) 1.30 (m, 2H)and 
0.83 (t, 3H); Water: 1H NMR δ 3.3 (s, 2H).30,31 Since it was assumed that all surface water 
and solvent are removed after sufficient drying, the characteristic peaks were integrated to 
determine the 1-butanol content. As previously stated, esomeprazole will demonstrate 
tautomerism in solution. DMSO-d6, a slow exchange solvent, was utilized in an effort to 
help reduce these effects in solution.32 The multiplet occurring at 8.25 ppm is characteristic 
of esomeprazole, uneffected by tautomerism, and signifies a single proton, while the triplet 
at 0.84 ppm is representative of the methylene protons of 1-butanol. Integrating these peaks 
confirmed that there are still 0.3 1-butanol molecules per esomeprazole magnesium in the 
dried sample. Water, seen at 3.33 ppm, cannot be accurately quantified in this method due 
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to inevitable impurities in the NMR solvent. These impurities arise from DMSO’s affinity 
for water; it cannot be dried completely over molecular sieves.33 
The structure of esomeprazole magnesium dihydrate/1-butanol solvate contains many 
different functional groups. IR spectroscopy was utilized to help confirm the presence of 
esomeprazole, water and 1-butanol after a sample had been dried under vacuum (see 
Appendix A, Figure A -2). Table 0.2 shows the absorption frequencies for these functional 
groups. The peaks presented are characteristic of esomeprazole with a broad peak at 
approximately 3000 cm-1 from the O-H stretching in water and 1-butanol. The peak 
representative of the N-H in the benzimidazole, usually seen around 3400 cm-1, is not 
observed. This is due to overlapping with the frequencies of the O-H stretching from 
coordinated and non-coordinated solvent molecules. Compared to free esomeprazole, no 
change in frequency is seen for the pyridinic nitrogen. This agrees with the molecular 
structure determined with single crystal XRD, where esomeprazole is coordinating through 
benizimidazolic nitrogen and sulfoxide oxygen. The frequencies observed are in close 
agreement with the calculated IR spectra for omeprazole co-ordinated to different metal 
centers.28 
Table 0.2: IR spectroscopy absorption frequencies and corresponding functional 
groups. 
Functional 
Group 
Absorption Frequency 
(cm-1)  
Type of Vibration 
sulfoxide 1076 S=O stretching34 
methoxy 1199 C-O stretching34 
methoxy 1228 C-O stretching34 
amine 1409 N-H bending28 
pyridine 1569 C=N stretching28 
benzimidazole 1612, 1588 C=N stretching28 
aromatic 2970 
C=C-H asymmetric 
stretching34 
alcohol/water 3100-2800 O-H stretching35 
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In an attempt to confirm the total solvent content in the crystal lattice, thermogravimetric 
analysis (TGA) was performed. The TGA results revealed two mass losses for this solvate. 
The first step can be attributed to the loss of solvent in the lattice, while the second step 
can be accredited to the decomposition of the sample. The desolvation resulted in a loss of 
7.6% of the total mass. These results are consistent with the 1H NMR analysis of 0.3 1-
butanol and two water molecules per esomeprazole magnesium. The spectrum obtained 
from TGA confirms that the esomeprazole magnesium water/1-butanol solvate loses 
solvent from the lattice when dried under vacuum. TGA was also conducted after heating 
the sample to 120°C under vacuum, and the same results were acquired. The second mass 
loss begins at 200 °C, typical for the decomposition of esomeprazole magnesium.29 
 
Figure 0.7: TGA of the title sample showing two mass losses. The first loss of 7.6% is 
desolvation, while the second loss is decomposition of the esomeprazole molecule. 
Differential scanning calorimetric analysis was performed on the esomeprazole 
magnesium water/1-butanol solvate as well (Figure 0.8). The pattern shown can be 
described as an exothermic melting via decomposition. Amorphous esomeprazole 
magnesium is known to display an exothermic peak at approximately 200 °C.36 When DSC 
was run on the starting material, the exothermic peak was seen at 181°C. From Figure 0.8, 
the water/1-butanol solvate decomposes at 200 °C. This increase in decomposition 
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temperature implies an increase in stability. The peak shown below is broader than that of 
the amorphous API; the width at half height is 13.3 °C, while the width is 5.8°C for 
amorphous esomeprazole magnesium. The broadening agrees with the results from TGA 
and 1H NMR that show solvent is still present in the lattice. In addition to this peak, the 
DSC curve of the title compound also shows an endotherm at 175 °C. This curve matches 
known results for esomeprazole magnesium dihydrate, which aids in validating the 
assumption that some of the solvent is being removed after vacuum drying, leaving 
esomeprazole magnesium dihydrate with some 1-butanol molecules.17 
 
Figure 0.8: The DSC curve of esomeprazole magnesium water/1-butanol solvate. The 
curve was obtained from 25-350 °C at a heating rate of 5 °C/minute. An exotherm 
characteristic of esomeprazole magnesium is seen at 200 °C as well as an endotherm 
at 175 °C. 
The stability of this compound is further investigated by DVS; the subsequent isotherm is 
shown in Figure 0.9. In sorption cycles 1 and 2, there is a 5.3% mass increase. The 
adsorption/desorption of water is a reversible process in the title compound. Since the 
sample reverted to the initial mass, the water adsorbed can be said to be on the surface of 
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the API. The behaviour of this isotherm implies that the structure of the title compound is 
highly crystalline. 
 
Figure 0.9: Esomeprazole magnesium water/1-butanol adsorption of water at 
increasing humidity followed by desorption at decreasing humidity. The cycle is 
repeated to give two isotherms. 
Conclusion 
This is the first single crystal structure reported that displays esomeprazole coordinated to 
a metal center. Analysis of the crystal structure shows that water is bound to magnesium 
cation as well filling the channels of the lattice. The covalently bonded waters are much 
more strongly kept in the lattice than those maintained by hydrogen bonding. The discovery 
of this esomeprazole magnesium solvate could have applicability to the development of 
improved pharmaceutical solid dosage forms. 
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Chapter 4 
Co-amorphous form of curcumin-folic acid dihydrate with 
increased dissolution rate 
Curcumin is a naturally occurring pharmaceutical derived from turmeric. Despite its many 
medicinal properties, such as being an antioxidant, anti-inflammatory, tumor reducer, etc., 
applications of curcumin are restricted due to its low aqueous solubility and consequently 
its poor bioavailability. By converting the solid state of poorly water soluble active 
pharmaceutical ingredients to co-amorphous mixtures, solvates, co-crystals and eutectics, 
the solubility can be significantly improved. In this study, US Food and Drug 
Administration (FDA) approved excipients were screened for their ability to form novel 
solid states with curcumin to increase its aqueous solubility. Excipients were screened 
based on their molecular complementarity with curcumin that was determined using 
Mercury software. From this screening, it was found that a co-amorphous mixture can be 
formed between curcumin and folic acid dihydrate that has potential as a prenatal or a 
women’s health drug due to its use in preeclampsia and ovarian cancer treatments. This 
mixture was found to have an increased dissolution rate when compared with curcumin. 
After one hour, 175 mg/L of curcumin was dissolved from the co-amorphous mixture, 
while only 45 mg/L was dissolved from curcumin Form I. The co-amorphous mixture is 
stable as it was shown to keep its amorphous behavior after 24 hours in solution at elevated 
temperatures. Eutectics were found to form between curcumin and biotin, carbmazeapine, 
ethyl paraben, paracetamol, suberic acid, succinic acid and L-tyrosine. Screening with 
other excipients led to no novel solid state formation; however, an improved synthesis 
method for curcumin Form II in the presence of dextrose is presented. 
Introduction 
Curcumin, with many potential applications as an antioxidant1, anti-inflammitory2, 
colourmetric sensor3, tumor reducer4, holds a high level of interest in food and 
pharmaceutical industries. Though it is safe for ingestion up to 8000 mg/day5, curcumin is 
limited in function due to its extremely low water solubility (<0.1 mg/mL), which leads to 
inadequate bioavailability.6 Curcumin is unstable and known to decompose in neutral and 
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basic conditions. Degradation products include trans-6-(4'-hydroxy-3'-methoxyphenyl)-
2,4-dioxo-5-hexenal as the major product, while vanillin, ferulic acid and feruloyl methane 
are the minor products.7 Vanillin has been shown to have its own pharmaceutical 
applications, but since its concentration is extremely low as a degradation product, it cannot 
be claimed as the reason for curcumin’s bioactivity.8 All of these products have low 
toxicity, but degradation occurs rapidly. In order to increase its prevalence in commercial 
use, the stability and solubility issues of this naturally occurring active pharmaceutical 
ingredient (API) need to be addressed. 
Changing the solid form of the API as a means of increasing its solubility is a very popular 
technique in the pharmaceutical industry. Common solid forms include salts, solvates, 
eutectic mixtures, co-crystals and co-amorphous mixtures. Salts occur from the formation 
of ionic bonds between an API and one or more excipients. A solvate occurs when solvent 
molecules are incorporated into the lattice during crystallization through intermolecular 
bonding.  A eutectic mixture is composed of fine crystals of each component that are mixed 
very closely, and when an API forms a eutectic with a water soluble compound, the 
dissolution rate of the drug  increases.9,10 Co-crystals, which have been steadily gaining 
interest in the pharmaceutical industry11, are more comparable to solvates. They are 
composed of two or more components, termed API and co-former(s), that are 
intermolecularly bonded (mainly hydrogen bonding) to form a crystal lattice. All 
components of a co-crystal are found in stoichiometric amounts and should be overall 
neutral and solid at ambient conditions.   
Co-amorphous solids occur when two components become amorphous due to interaction 
with one another. Intermolecular bonding between API and excipient impedes the 
arrangement of individual molecules into separate lattices and results in an amorphous 
material.12 Amorphous pharmaceutical compounds have been shown to have increased 
solubility in comparison to their crystalline counterparts. For instance, indomethacin, 
glucose, glibenclamide, griseofluvin, iopanoic acid and polythiazide were all 
experimentally shown to have solubility ratios (amorphous:crystalline) ranging from 1.4 to 
24.13–18 Since the amorphous form is the most energetic, this solid state should greatly 
increase solubility and bioavailability.13 However, compounds that are amorphous have 
been shown to have low stability and will tend to crystallize if exposed to moisture.19 Co-
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amorphous mixtures are shown to be not only high in solubility, but also possess high 
stability and are easily formed via grinding or milling. Co-amorphous systems have shown 
to not only increase the dissolution rates relative to crystalline materials, but also compared 
to their individual amorphous components.20 Co-amorphous mixtures of naproxen, 
indomethacin, simvastatin, carbamezapine, ritonavir and lurasidone hydrochloric acid with 
various excipients show increases in dissolution rate up to 200-fold when compared to 
starting materials.21–28 Various amino acids have been displayed to form co-amorphous 
mixtures with low solubility APIs and were stable up to 4-6 months at 40 °C/0% relative 
humidity, which is much longer than most amorphous drugs.  
Since co-crystals have shown the ability to enhance solubility and bioavailability of Class 
II and IV drugs29–38, attempts were made to produce co-crystals of curcumin using several 
co-formers. Before choosing potential co-formers for co-crystallization, a thorough 
literature review was carried out to understand current state of the art. Curcumin has been 
reported to form co-crystals with several co-formers listed in Table 0.1. However, 
formation of co-crystals is not always successful and sometimes results in eutectic 
mixtures; some known curcumin eutectics have been listed in Table 0.2. Curcumin, which 
has an intrinsic dissolution rate (IDR) of 0.0061 (mg/cm2)/min39, showed an increase in 
IDR for all of these solid forms (reported in Tables 4.1 and 4.2). The most successful co-
crystal is with pyrogallol, showing well over a tenfold increase in IDR and nearly five times 
as soluble in 40% ethanol.40 There is also a drug-drug co-amorphous mixture of curcumin 
and artemisinin with an IDR that is 2.6 times faster than curcumin in 60% EtOH.41 The 
next most successful solid state, with IDR of 0.0647 IDR (mg/cm2)/min, is the eutectic 
mixture of curcumin with nicotinamide.39 Some co-formers that simply resulted in a 
physical mixture include: L-maleic acid39,  catechol40 and orcinol.40 
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Table 0.1: Known Curcumin Co-crystals and Their Intrinsic Dissolution Rates. 
aAPI is the curcumin derivative bisdesmethoxycurcumin 
IDR = Intrinsic dissolution rate 
   NR = not reported 
 
Table 0.2: Known Curcumin Eutectics and Their Intrinsic Dissolution Rates. 
 
 
 
 
 
 
In addition to increasing the bioavailability, co-crystals, as well as co-amorphous and 
eutectic mixtures have also been employed to increase therapeutic effect, reduce the 
number of prescriptions and reposition drugs by means of drug-drug combinations.46 Since 
curcumin is  known to be anti-inflammatory, it could be combined with another anti-
inflammatory drug to increase potency or combined with a drug that is usually prescribed 
alongside an anti-inflammatory drug to reduce the number of prescriptions. In this work, 
we have made attempts to prepare new solid forms of curcumin, including drug-drug 
Co-former IDR 
(mg/cm2)/min 
Co-former IDR 
(mg/cm2)/min 
2-aminobenzimidazole41 0.023 nicotinamide23 0.040 
4-4’-bipyridine-N,N’-dioxide42 NR phloroglucinol43 0.0166 
caffeinea, 44 NR piperazine44 NR 
ibuprofen sodium44 NR piperidine44 NR 
isonicotinamide44 NR L-prolinea,44 NR 
L-lysine41 0.029 pyrogallol40 0.09364 
methylparaben45 NR resorcinol40 0.03761 
naproxen sodium44 NR   
Co-former IDR 
(mg/cm2)/min 
ferulic acid39 0.0412 
hydroquinone39 0.0344 
p-hydroxybenzoic acid39 0.0270 
nicotinamide39 0.0647 
l-tartaric acid39 0.0132 
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mixtures. While the main aim was to produce co-crystals, eutectics have been formed along 
with a co-amorphous form of curcumin and folic acid dihydrate (CUR-FAD) with 
enhanced dissolution rate. 
Experimental 
Materials and Instruments 
Succinic acid, L-tyrosine and ethanol were purchased from Fisher Scientific (Mumbai, 
India), Alfa Aesar (Hyderabad, India) and Chemcon Specialty Chemicals Pvt Ltd 
(Vadodara, India), respectively. All other chemicals purchased were from Sigma Aldrich 
Chemicals Pvt Ltd (Bangalore, India). 
DSC analyses of solid samples were carried out on a NETZSCH STA 449F3 Jupiter 
(NETZSCH-Gerätebau GmbH; Selb, Germany) from 25-350℃ at a heating rate of 
10K/min, unless otherwise stated. Phase diagrams were obtained from plotting both the 
onset of the first endotherm and the peak temperature of the second endotherm.  Powder 
X-ray Diffraction (PXRD) studies were carried out using a Rigaku Miniflex instrument 
with Cu X-ray radiation. Scans were run at a speed of 1.00°/minute for 2θ values of 2.00-
40.00°. Infrared (IR) Spectroscopy results were obtained over 32 scans from 4000 cm-1 to 
500 cm-1 using a Vector 22 FT–IR spectrometer (Bruker; Milton, Canada). 
Preparation and characterization of curcumin and folic acid dihydrate 
(CUR-FAD) co-amorphous mixtures 
Liquid assisted grinding (LAG) with 5 drops of methanol was executed on equimolar 
amounts of curcumin and folic acid dihydrate using mortar and pestle for varying amounts 
of time.  
Equilibrium solubility and powder dissolution studies 
UV-Vis (ultraviolet visible) spectrophotometer (Agilent Cary 60 UV-Vis 
Spectrophotometer, Agilent Technologies, Santa Clara, USA) was used for estimation of 
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equilibrium solubility and powder dissolution rates. Three calibration curves (see 
Appendix B) were constructed using known concentrations of curcumin, folic acid 
dihydrate and CUR-FAD so the amount of curcumin and folic acid dihydrate released could 
be determined. The extinction coefficients were determined to be 45.4, 28.0 and 39.1 
L/mmol cm, respectively. Thermodynamic solubility was estimated by adding an excess of 
CUR-FAD (~20 mg) into 2 mL of 40% EtOH solution. The suspended solutions were 
allowed to stir at 37oC for over 24 hours. This was done in triplicate and concentration was 
determined using calibration curves.  
 To estimate dissolution kinetics, nine samples were prepared by adding excess 
(determined from thermodynamic solubility) CUR-FAD, which had been sieved through a 
150µm mesh, into 4 mL of 40% EtOH solution.  The solutions were stirred at 3.2 Hz and 
37 oC for a specified amount of time. Each sample was filtered using Arodisc 25 mm 
syringe filters with 0.45µmSupor membrane (Pall Corporation; Port Washington, USA), 
immediately diluted and concentration was estimated using UV-Vis spectroscopy. Powder 
dissolution studies were conducted in triplicate and the average values have been reported.  
Results and Discussion 
Solid State Formation 
To increase the amount of curcumin absorbed by the body and improve its applications in 
the pharmaceutical industry, several co-formers were screened to explore their ability to 
form different solid states with curcumin. The excipients investigated should be safe for 
human ingestion to have feasible pharmaceutical and food applications. Critical to 
successful screening is the choice of appropriate co-formers that will form strong 
intermolecular bonds. Using the molecular complementarity tool in Mercury,47 which takes 
into account factors such as molecular shape and polarity, a list of potential co-formers was 
constructed based on the molecular structure of Form I curcumin, the stable form.48 It 
should be noted that, like the successful co-formers that form solid states with curcumin, 
Mercury predicted success with heterosynthons (e.g. curcumin with carboxylic and amine 
functional groups), utilizing the enol as the strongest probable intermolecular bonding site. 
The list shown in Table 0.3, was then condensed to only include compounds suitable for 
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pharmaceutical applications. Analyzing the list, comparing it to the known co-crystals of 
curcumin and using the compounds present in the laboratory, led to the screening of 
succinic acid, suberic acid, ibuprofen, paracetamol, oxalic acid, l-tyrosine, N-
acetyltryptophan, carbamezapine, ethylparaben, folic acid, biotin and dextrose. 
Table 0.3: FDA Approved Potential Co-formers for Curcumin Co-crystals. 
Co-former Co-former 
Adipic acid 
 
L-methionine 
 
L-arginine 
 
L-phenylalanine 
 
t-butylhydroxyanisole  
 
Propylparaben 
 
Capsaicin 
 
Sorbic acid 
 
Ethylparaben 
 
Suberic acid 
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Folic acid 
 
Succinic acid 
 
L-glutamic acid  
 
L-tryptophan 
 
Lactose 
 
L-tyrosine 
 
 
A recognized co-crystal screening technique uses DSC (differential scanning calorimetry) 
as a rapid method for assessing potential co-formers. In this technique, DSC is run for three 
different ratios (1:1, 1:2 and 2:1) of the components.49 This should result in two endotherms 
representing the eutectic melt and melting of the co-crystal; each endotherm should be 
distinct from the melting of the API and co-former. Using this screening process, one can 
usually surmise if an API and co-former have capability of forming a co-crystal or eutectic. 
In case of ambiguous results, a phase diagram should be constructed. After running DSC 
for samples ground at varying molar ratios of curcumin and co-former, it was determined 
whether co-crystal formation was viable or if a eutectic would form. These results are 
confirmed with PXRD which will show new peaks for co-crystals, a combination of the 
peaks of the starting materials for eutectic and physical mixtures, or an amorphous pattern 
for co-amorphous mixtures. From analysis of PXRD and DSC, it was determined that 
physical mixtures were formed with dextrose, N-acetyltryptophan, and ibuprofen. This can 
be seen by the example with dextrose given in Figure 0.1 (a), where there is clearly no 
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converging in the phase diagram. Eutectics formed with biotin, carbamazepine, ethyl 
paraben, paracetamol, suberic acid, succinic acid and L-tyrosine. A phase diagram for the 
eutectic with suberic acid is given in Figure 0.1 (b). When combined with the PXRD shown 
in Figure 0.2, it is made clear that the product is a eutectic and not a co-crystal or co-
amorphous mixture. None of the screened co-formers were found to form crystals with 
curcumin; however, a co-amorphous mixture with folic acid dihydrate (CUR-FAD) was 
formed. 
 
Figure 0.1: Phase diagram for (a) the physical mixture of curcumin and dextrose and 
(b) the eutectic mixture of curcumin and suberic acid after grinding at varying molar 
ratios. Temperatures plotted in blue represent the onset of the first melting peak seen 
in DSC, while orange represents the temperature of the second peak.  
(a) 
(b) 
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Figure 0.2: PXRD patterns for (a) raw suberic acid, (b) raw curcumin, (c) curcumin 
form I, (d) form II, (e) form III, (f) 1:1 curcumin:suberic acid (CUR-SUB), (g) 1:2 
CUR-SUB, (h) 2:1 CUR-SUB, (i) 1:3 CUR-SUB, (j) 3:1 CUR-SUB, (k) 1:4 CUR-SUB, 
(l) 4:1 CUR-SUB acid and (m) 4:1 CUR-SUB acid heated to 133℃. 
 
Following the screening protocol, curcumin and folic acid dihydrate were initially ground, 
and PXRD patterns were recorded for 10, 20, 30, 60 and 90 minute intervals of liquid 
assisted grinding. As shown in Figure 0.3, the final product remained amorphous after 
grinding for 90 minutes. The PXRD patterns clearly show the loss of crystallinity, which 
is different when compared with the PXRD patterns of raw curcumin and folic acid 
dihydrate. In addition to PXRD, DSC heating experiments were also conducted throughout 
the grinding process. Error! Reference source not found. shows DSC thermographs for 
ground samples and those for curcumin and folic acid dihydrate. It is observed that the 
melting endotherm of curcumin at around 180oC is not present in the ground product and 
instead there is an exothermic peak (seen in Error! Reference source not found. (a) and 
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(b)). The magnitude of the peak corresponding to curcumin melting decreases gradually 
with heating, which indicates transition to an amorphous phase by grinding. These results 
clearly indicate that liquid assisted grinding (LAG) of curcumin with folic acid dihydrate 
results in a co-amorphous solid. 
 
 
Figure 0.3: PXRD patterns for CUR-FAD from LAG after (a) 90 min, (b) 60 min, (c) 
30 min, (d) 20 min, (e) 10 min, (g) raw folic acid dihydrate and (h) raw curcumin. 
 
Figure 4.4: DSC thermograph for CUR-FAD from LAG after (a) 90 min, (b) 60 min, 
(c) 30 min, (d) 20 min and (e) 10 min (f) raw folic acid dihydrate and (g) raw curcumin. 
Exothermic 
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To ensure that there is no decomposition of the starting materials and that a co-amorphous 
mixture is forming, both 1H NMR and FT-IR spectra were obtained for the ground samples. 
It is clear from Figure 0.5 that the solution NMR spectrum of CUR-FAD in DMSO-d6 
shows the characteristic peaks of curcumin as well as folic acid dihydrate. Also, there is no 
excess peak that would correspond to the decomposition of curcumin nor folic acid 
dihydrate.  
 
 
Figure 0.5: solution 1H NMR spectra for (a) CUR-FAD, (b) raw folic acid dihydrate 
and (c) raw curcumin in DMSO-d6. 
 
Normalized FT-IR spectra are shown in Figure 0.6, and analysis suggests interactions 
between curcumin and folic acid dihydrate but no decomposition. It should be noted that 
the peaks in the 3500-3200 cm-1for the N-H stretching in folic acid dihydrate lose their 
intensity; this is most likely due to the involvement of weak intermolecular bonding with 
the API. The peak for the phenolic O-H stretching in curcumin50 at 3509 cm-1 is not seen 
in the spectrum of the co-amorphous product, and the carbonyl stretching51 at 1691 cm-1 of 
folic acid dihydrate is shifted to 1697 cm-1for CUR-FAD.  There is also a shift in the 
carbonyl stretching of curcumin from 1627 cm-1 to 1623 cm-1, implying that it is involved 
in the interaction, too.  No indication of degradation during grinding in addition to 
implications for increased interaction between curcumin and FAD further confirms that a 
co-amorphous solid phase has been formed. 
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Figure 0.6: FT-IR spectra for (a) CUR-FAD, (b) raw folic acid dihydrate and (c) raw 
curcumin. 
Solubility and Dissolution Rate Tests 
Since the objective in forming a new solid state with curcumin was to increase the amount 
absorbed in the body, powder dissolution rate studies were conducted. Excess amount of 
CUR-FAD was placed in nine separate vials which were then each filled with 2 mL of 40% 
EtOH solution at 37oC. Vials were stirred at 3 Hz for up to 4 hours, filtered and diluted, 
then analyzed using UV-Vis spectrophotometer. Figure 0.7 shows dissolution profiles for 
raw curcumin and the co-amorphous solid. When compared with curcumin, there is an 
increase in dissolution rate for the co-amorphous product. The dissolution rate for the co-
amorphous product was found to be similar to the pyrogallol co-crystal (about 182 mg of 
curcumin/L after 4 hours), which has the largest increase in IDR compared to other 
curcumin co-crystals. Thermodynamic equilibrium solubility studies were also conducted 
over 24 hours at 37oC by adding excess CUR-FAD to 2 mL of 40% EtOH solution. It was 
found that 458 ± 25 mg/L and 328 ± 31 mg/L of curcumin and folic acid dihydrate were 
dissolved, respectively. Using the area under the curve, the amount of curcumin dissolved 
in four hours from the co-amorphous mixture is 41.2 ± 3.8 g h/L, which is much greater 
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than that of curcumin form I (12.2 g h/L).25 The PXRD pattern of the remaining powder in 
solution after 24 hours is shown in Figure 0.8. The overall pattern is still amorphous in 
nature, but characteristic peaks can be seen at 2θ values of 17.3 and 8.9 for curcumin and 
13.0 and 10.9 for folic acid dihydrate. Thus, it can be stated that the co-amorphous mixture 
is still relatively stable since it remains highly amorphous in nature after 24 hours in 
solution at an elevated temperature. 
 
 
Figure 0.7: Powder dissolution rate studies for CUR-FAD compared with 
curcumin.25 
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Figure 0.8: PXRD pattern of powder from thermodynamic equilibrium solubility. 
 
Folic acid is a form of the water soluble vitamin B-9, and it is highly encouraged to take 
during pregnancy for both maternal and fetal health.52 Curcumin is also known to reduce 
placental inflammation, a common symptom of preeclampsia that occurs in up to 8% of 
pregnancies.53,54 When combined, this new drug-drug combination has the potential to be 
repositioned as a prenatal drug. Both curcumin and folic acid have been shown to be 
effective in the treatment and pre-treatment of ovarian cancer; once again, this could lead 
to a reposition of this co-amorphous mixture as a women’s health drug and could 
potentially lead to a lower number of drugs prescribed.55,56 
Formation of Curcumin Form II 
When performing solution crystallization to synthesize curcumin co-crystals, Form II 
curcumin crystals were found to grow in the presence of dextrose. Solution crystallization 
was performed for this pair due to ambiguity in the PXRD patterns (i.e. appeared to show 
novel peaks). While this was not the initial aim of these experiments, it is still beneficial 
since this curcumin polymorph has a faster dissolution rate. It is the metastable polymorph, 
so Form II is generally not stable and will not form easily relative to Form I. Since it is 
crystallized in the presence of dextrose, this makes the process safer for pharmaceutical 
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and food applications. Also, this procedure does not involve dimethyl sulfoxide, a difficult 
to remove solvent, nor cooling like some known processes.40 A simple method is proposed 
from which Form II crystals can be grown via slow evaporation, or by rapid evaporation 
(i.e. heating the solution close to boiling point of solution), from a solution of 90% 
methanol with equimolar dextrose present. The crystals grown were of X-ray quality and 
resulted in the confirmation of Form II curcumin that crystallizes in the orthorhombic space 
group of P ca21 (shown in Figure 0.9).58 Further research should be conducted to test the 
validity and feasibility of this method on a larger scale. 
 
Figure 0.9: Asymmetric unit of Form II curcumin with space group of P ca21 formed 
via slow evaporation from 90% methanol in the presence of dextrose. Hydrogen 
atoms are omitted for clarity. C: grey; O: red. 
Conclusion 
Curcumin is a natural drug product that is found to have many health benefits; however, 
its use in industry is limited by its very low aqueous solubility. To increase the 
bioavailability of curcumin, screening for a novel solid state was conducted. The excipients 
screened were chosen using a combination of the supramolecular synthon approach, 
computational molecular complementarity and knowledge of known curcumin co-crystals. 
It was found that physical mixtures would form with dextrose, N-acetyltryptophan, and 
ibuprofen, while eutectics would form with biotin, carbmazeapine, ethyl paraben, 
paracetamol, suberic acid, succinic acid and L-tyrosine. Of particular interest of this work 
is the result of screening with folic acid dihydrate. Folic acid dihydrate was chosen due to 
its approved molecular complementarity with curcumin. A novel solid state of curcumin is 
presented in this paper as a co-amorphous mixture with folic acid dihydrate (CUR-FAD). 
Using liquid assisted grinding, the mixture became co-amorphous. This mixture, which can 
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be repositioned in the pharmaceutical industry as a prenatal, has shown to dissolve faster 
than curcumin in aqueous solutions. At 60 minutes, 175 mg/L of curcumin is dissolved 
from CUR-FAD; this is much more efficient than curcumin, which is found to dissolve 
about 40 mg/L at 60 minutes. The co-amorphous mixture is found to keep its amorphous 
behaviour after 24 hours in solution at 37oC. Further work should be conducted to see the 
stability of this mixture. Co-amorphous mixtures have been shown to be more stable than 
a single amorphous compound but retain the increased solubility and dissolution rates; 
therefore, more excipients should be screened for this type of solid state. An improved 
method is given for the formation of metastable curcumin Form II crystals which is 
industry friendly since it is done in the presence of dextrose and no methanol is included 
into the molecular structure. 
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 Chapter 5 
Efforts to Increase the Solubility of Rufinamide 
Rufinamide is an active pharmaceutical ingredient (API) that is used to treat a form of 
childhood epilepsy called Lennox-Gastaut syndrome that is characterized by having 
multiple seizure types. This API has a broad-spectrum antiepileptic with low adverse 
effects. Rufinamide is considered a Class IV API by the Biopharmaceutics Classification 
System, which means that it has low solubility and low permeability. Since patients with 
Lennox-Gastaut syndrome are usually children and are often taking multiple medications, 
it would be advantageous to increase the solubility of this drug to reduce the required 
dosages. To date, there are no salts, co-crystals, solvates, etc. of this drug; its structural 
polymorphs are the only solid state forms discovered. We attempted to increase the 
dissolution rate of rufinamide by choosing potential excipients and conducting extensive 
screening to form co-crystals or other solid state forms. No novel solid states of rufinamide 
with excipients were produced. The excipients that were chosen all had potential to form 
intermolecular bonds and passed a computer-based screening test. However, the molecular 
structure of a metastable polymorph termed modification B of rufinamide was obtained. 
Also reported is an accelerated procedure to produce modification B in the presence of 
citric acid.  
Introduction 
Lennox-Gastaut syndrome is a serious form of childhood epilepsy characterized by 
multiple seizure types and often cognitive impairment. This syndrome frequently continues 
into adulthood, and the seizures are generally not responsive to typical antiepileptic drug 
care.1 Rufinamide (shown in Figure 0.1) is an anticonvulsant that acts by reducing the firing 
of sodium dependent action potentials in treating patients with Lennox-Gastaut syndrome.2 
This API is a broad-spectrum antiepileptic drug with low drug interaction and good adverse 
event profile.3 While it is proven to be effective, this drug has very poor aqueous solubility 
and relatively low permeability, so it is considered to be BCS (Biopharmaceutics 
Classification System) Class IV.4  
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To date, there are no known co-crystals, solvates, eutectics or co-amorphous mixtures 
involving rufinamide; however, there are multiple polymorphs.5,6 A polymorph is a solid 
crystalline phase of a given compound resulting from the possibility of at least two different 
arrangements of molecules of that compound in the solid state.7 Some of these polymorphs 
are given below in Table 0.1. Modification A is shown to have better thermodynamic 
stability; Modification C will transform to A or B at room temperature. The molecular 
structures of these polymorphs are not given in the CSD (Cambridge Structural Database). 
Table 0.1: Some polymorphs of rufinamide 
Polymorph Space Group Crystal System 
Modification A Pna21 orthorhombic 
Modification B P-1 triclinic 
Modification C P21/C monoclinic 
Looking at the chemical structure in Figure 1, there are multiple sites for potential 
intermolecular bonding between rufinamide and excipient molecules. Supramolecular 
synthons are structural units within supermolecules which can be formed and/or assembled 
by known or conceivable synthetic operations involving intermolecular interactions.8 Since 
amide groups are known to form both heterosynthons (e.g. with carboxylic acids) and 
homosynthons, molecules with either type of functional group should be screened for  
potential novel solid state forms with rufinamide.9 
 
Figure 0.1: Molecular structure of rufinamide. 
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Materials and Methods 
Rufinamide modification A was donated by Apotex Pharmachem Inc. (Branford, Canada). 
Solvents and excipients were obtained from Sigma Aldrich (Oakville, Canada). Screening 
of excipients for solid states was done via liquid assisted (ethanol) and neat grinding at 
various molar ratios for 20 minutes with mortar and pestle. Solution crystallization in 
various solvent systems was also attempted at varying molar ratios via slow evaporation at 
ambient conditions or cooling crystallization at a rate of 10 °C /hour. Theses screenings 
did not result in novel solid state formation. Bulk modification B was obtained by 
dissolving citric acid (100 mg) and rufinamide modification A (100 mg) in DMSO (6 mL) 
at 40°C for 2 hours. The mixture was turbid, so filtration was required and an additional 1 
mL of DMSO was added. Next, the solution was left at atmospheric conditions until 
needle-like crystals formed that were filtered and dried under vacuum at 60°C for three 
hours. Single crystals were grown via slow evaporation from methanol at ambient 
conditions, and Bruker Apex II Diffractometer with Mo X-ray radiation was used to obtain 
the crystal structure. 1H NMR spectrum was collected on a Mercury VX 400 MHz machine. 
Powder X-ray Diffraction was obtained from a Rigaku Miniflex instrument with Cu X-ray 
radiation. Scans were run at a speed of 1.00°/minute for 2θ values over 2° to 40°. 
Thermogravimetric analysis and differential scanning calorimetry were conducted on the 
Mettler-Toledo STARe 851e and 822e instruments, respectively, at a heating rate of 10 
°C/minute from 25-350 °C. 
Results and Discussion 
Since Class IV drugs are undesirable, increasing the solubility of rufinamide was attempted 
through solid form screening. Co-crystal screening via grinding and solution methods was 
conducted in an attempt to form novel solid states of rufinamide with a host of excipient 
molecules. To help choose an appropriate co-former, multi-component screening based on 
molecular complementarity was conducted via Mercury software.10 This software uses the 
shape, polarity and hydrogen bonding potential of the API to determine which excipients 
(from a list of the most commonly used co-crystal formers) may form a co-crystal based 
on the statistics of other co-crystal forming pairs. At the time of screening, none of the 
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molecular structures of rufinamide’s polymorphs were available in the Cambridge 
Structural Database (CSD). While it is not essential to have the molecular structure of the 
API to use this screening technique (e.g. a 3D drawing of the molecule would suffice), 
much more accurate results can be obtained if the structure of the API is available. Methyl 
1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylate, an intermediate in the synthesis of 
rufinamide, is accessible in the CSD and contains an ester as opposed to the amide group 
seen in Figure 0.1. The crystal was shown to form weak intermolecular C-H⋯O and C-
H⋯N hydrogen bonds that link the molecules into chains along the b-axis.11 This molecular 
structure was modified by simply changing the functional group to an amide so that it 
exemplified rufinamide. Once modified, this compound resulted in an extensive list of 
potential co-formers for co-crystal formation. This list led to many possible excipients to 
screen, so it was narrowed to include only those approved by the US Food and Drug 
Administration (FDA) that had strong capability to form intermolecular bonds. Excipients 
screened included citric acid, urea, thiourea, nicotinamide, sorbitol, L-(+)-histidine, L-
threonine, ascorbic acid, 4-aminobenzoic acid, propylene glycol, folic acid dihydrate, L-
alanine, L-glutamic acid, mandelic acid, succinic acid, lactose monohydrate, chitosan and 
L-tyrosine. Many different screening techniques, such as solvent crystallization and the 
grinding/DSC methods were employed as an attempt to form a novel solid state.   Though 
extensive screening with many excipient molecules was conducted, no novel co-crystals, 
co-amorphous, solvates or eutectic mixtures were discovered. 
Rufinamide Modification B 
In order to investigate the underlying reason, successful attempts were made to grow single 
crystals of rufinamide modification B and its molecular structure was obtained through 
single crystal XRD (X-ray diffraction). By dissolving rufinamide modification A in 
methanol and allowing slow evaporation, modification B crystallized out as colorless, 
needle-like crystals. While this unit cell is known, its molecular structure is not published 
and, as mentioned, cannot be found in the CSD. The sample was mounted on a Mitegen 
polyimide micromount with a small amount of Paratone N oil. All X-ray measurements 
were made on a Bruker Kappa Axis Apex2 diffractometer at a temperature of 110 K. The 
unit cell dimensions were determined from a symmetry constrained fit of 9962 reflections 
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with 5.02° < 2𝜃 < 68.16°. The data collection strategy involved ω and ϕ scans up to 68.602° 
(2θ). The frame integration was performed using SAINT.12 The resulting raw data was 
scaled and absorption corrected using a multi-scan averaging of symmetry equivalent data 
using SADABS.13 The structure was solved by using a dual space methodology using the 
SHELXT program.14 All non-hydrogen atoms were obtained from the initial solution. All 
hydrogen atoms were introduced at idealized positions and were allowed to ride on the 
parent atom. The structural model was fit to the data using full matrix least-squares based 
on F2. The calculated structure factors included corrections for anomalous dispersion from 
the usual tabulation. The structure was refined using the SHELXL-2014 program from the 
SHELXTL suite of crystallographic software.15 Graphic plots were produced using the 
Mercury program suite (Summary of crystal data in Table 0.2).16  
Table 0.2: Summary of Crystal Data of Rufinamide Modification B. 
Formula C10H8F2N4O 
Formula Weight (g/mol) 238.20 
Crystal Dimensions (mm) 0.377 × 0.137 × 0.086 
Crystal System Triclinic 
Space Group P -1 
Temperature, K 110 
a, Å 5.2943(10) 
b, Å  11.936(5) 
c, Å  17.121(6) 
𝛼,° 71.540(14) 
𝛽,° 87.719(9) 
𝛾,° 77.255(8) 
V, Å3 1000.5(6) 
Z 4 
F(000) 488 
𝜌 (g/cm) 1.581 
𝜆, Å, (MoK𝛼) 0.71073 
𝜇, (cm-1) 0.133 
R1 0.0632 
wR2 0.1131 
GOF 1.033 
Maximum shift/error 0.001 
Min & Max peak heights on final ΔF Map (e-/Å) -0.287, 0.519 
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Modification B of rufinamide was found to crystallize in the space group P-1 with Z = 4. 
The packing in the unit cell is shown in Figure 0.2. Intermolecular N-H⋯O hydrogen 
bonding occurs between the amide groups of distinct molecules (Figure 3). There is also 
N-H⋯N bonding between amide groups and nitrogen of the triazole. The bond lengths 
range from 2.890 to 3.057 Å and are representative of strong hydrogen bonding between 
molecules. The shortest and strongest intermolecular bonds are the N-H⋯O bonds (i.e. 
bonds a, b and c in Figure 0.3), which is known to be a convincing homosynthon. 
Intriguingly, the homosynthon is formed between three distinct rufinamide molecules as 
opposed to two molecules, which is more common. This is evidently illustrated in Figure 
0.4. The presence of an amide strengthens the intermolecular bonding, which is noticeable 
when compared to the weak hydrogen bonding of the rufinamide derivative mentioned 
earlier. It is worth mentioning that halogen bonding was observed in the structure of 
rufinamide between fluorine groups and the aromatic benzene rings of individual 
molecules. Weak intermolecular bonding is also seen between hydrogen molecules of the 
CH2 group and the triazole nitrogen.  
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Figure 0.2: Molecules of rufinamide modification B in one unit cell. F: green, O: red, 
N: blue, C: grey and H: white. 
 
Figure 0.3: Strong hydrogen bonding between the molecules in the lattice are shown 
in black dotted lines (labelled a-d); hydrogen atoms have been omitted for more 
clarity. F: green, O: red, N: blue, C: grey. 
(a) 2.890 Å 
(c) 2.937 Å 
(b) 3.038 Å 
(d) 3.057 Å 
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Figure 0.4: Intermolecular homosynthons between (a) two and (b) three amide groups 
from distinct molecules. 
Further Screening 
Once the molecular structure of rufinamide modification B was obtained, it was possible 
to run the multi-component screening through Mercury using the molecular structure of 
the modification B, instead of a compound with a structure similar to rufinamide, as 
discussed earlier. A much narrower list of potential co-formers was obtained, which could 
lead to more accurate screening. For instance, succinic acid was a potential co-crystal 
former with the modified rufinamide intermediate; however, it did not pass the statistical 
screening with rufinamide modification B due to issues with shape and size 
complementarity. The FDA approved list from the second screening computer generated 
group of suggested co-formers is given in  
Table 0.3. Some of the potential co-formers that were suggested for the modified 
rufinamide derivative showed negative results for co-crystal formation with modification 
B. This coincides with the statement that co-crystal formation is very dependent on the 
shape of the molecule, not solely hydrogen bond formation capabilities.10 
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Table 0.3: FDA approved co-formers from CSD screening with rufinamide 
modification B 
L-arginine  L-tyrosine  
L-methionine  lactose 
L-phenylalanine  citric acid  
L-tryptophan  capsaicin 
  
Another extensive screening was conducted, but this time with modification B as the 
starting solid form of the API and the co-formers listed above; however, still no new solid 
states were discovered. This was peculiar due to the many potential sites for hydrogen 
bonding in rufinamide. Also, triazole derivatives have been shown to readily form co-
crystals with compounds containing carboxylic acid groups.17  
When analyzing the chemical structure of rufinamide, it seems like a good candidate for 
incorporating an excipient into the crystal lattice. There are multiple sites for hydrogen 
bonding (e.g. amide, triazole and halogen functional groups) and its low aqueous solubility 
makes it an interesting target for co-crystal, co-amorphous, eutectic or solvate formation. 
Additionally, the Z’ value (i.e. the molecules in the asymmetric unit) for rufinamide 
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modification B is 2, and it has been shown that molecules with a Z’>1 have a stronger 
tendency to form co-crystals.18 Furthermore, when screened for potential co-crystal co-
formers, many molecules were suggested with eight of them being FDA approved.. It has 
also been previously shown that triazole groups are capable of forming hydrogen bonds 
with dicarboxylic acids leading to the formation of co-crystals, but rufinamide was unable 
to form any novel solid state with the molecules listed in Table 3.6 It was observed that 
rufinamide tended to form needle-like crystals and would often form a jelly-like solution 
during the crystallization process (i.e. a hydrogel). In order for a novel solid state to form, 
the intermolecular bonding force between API and excipient needs to be stronger than the 
API-API and excipient-excipient intermolecular bonding force. Perhaps the intermolecular 
forces between molecules of rufinamide are too strong to overcome by the attempted co-
former molecules. As stated, there are no solid states of rufinamide in literature that involve 
excipient addition into the crystal lattice. Amide-amide bonds are very strong, and it is 
shown in the crystal structure of rufinamide modification B that this homosynthon is a 
stabilizing force. The high stability of the rufinamide crystal structure would also explain 
why grinding did not help in the formation of any new forms: the mechanical forces were 
not strong enough to break the bonds.  
Another suggestion as to why no novel solid states were produced with excipient molecules 
could be due to solubility issues. Rufinamide has very poor solubility in most solvents and 
had to be heated to dissolve fully. Often, solvents such as dimethylformaide (DMF), 
dimethylsulfoxide (DMSO) and dimethylacetamide (DMAC) were used, in which the 
excipients were very highly soluble. These solubility issues could lead to the fast 
crystallization of rufinamide before any co-former had the chance to interact with it.  
Results from Screening with Citric Acid 
While no novel solid state form was obtained through screening with citric acid similar to 
other employed excipients, some interesting results were observed in the case of citric acid. 
Crystals were obtained by dissolving citric acid and rufinamide modification A in DMSO; 
the solution was left at atmospheric conditions until solids were formed. The crystals 
obtained were filtered and dried under vacuum for solvent removal. When compared with 
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the starting material (i.e. modification A), seemingly novel powder XRD (PXRD) pattern 
was recorded; which is illustrated in Figure 0.5 (a). The differential scanning calorimetry 
(DSC) thermograph ( Figure 0.5 (b)) appeared very similar to that of rufinamide 
modification A, which is not characteristic of co-crystal formation. Solution 1H NMR 
(nuclear magnetic resonance) was run to identify the main components of the solid and can 
be seen in Figure 0.6. The NMR spectrum revealed that rufinamide was present (i.e. the 
product’s spectrum matches that of the starting material), so the experimental conditions 
did not lead to decomposition of the API. Interestingly, when compared to the spectrum of 
pure citric acid, this starting material is undoubtedly absent in NMR of the product; 
indicating that citric acid did not crystallize with rufinamide. These findings led to further 
analysis of the PXRD pattern, which revealed that the product was the metastable 
modification B. This was proven by matching the diffraction pattern with the pattern that 
was simulated from the obtained single crystal results.  
 
Figure 0.5: (a) PXRD patterns and (b) DSC thermographs for rufinamide 
modification A (black) and rufinamide modification B obtained from solution 
(purple). 
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Figure 0.6: 1H NMR spectra for (a) citric acid, (b) rufinamide modification A and (c) 
rufinamide modification B in DMSO-d6. 
The proposed process to obtain modification B is much quicker than slow evaporation and 
resulted in a more homogeneous product with increased crystallinity. The procedure was 
replicated by using different acids (summarized in Table 0.4), but the product either did 
not crystallize or decomposed. Citric acid has a pKa1 of 3.08, while oxalic acid has a pKa1 
of 1.23. Oxalic acid is much stronger acid and leads to the decomposition of rufinamide. 
Formic acid and ascorbic acid have pKa1 values of 3.75 and 4.10, respectively. They are 
not strong acids and comparable to citric acid. While rufinamide did not decompose using 
these acids, it resulted in the crystallization of modification A. Next, the solvent type was 
varied (i.e. DMF, DMAC), but the results could not be duplicated. Clearly, there must be 
some solvent effects that are present when DMSO is used.  
 
 
 (ppm) 2 13 
(a) 
(b) 
(c) 
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Table 0.4: Attempted acids for synthesis of rufinamide modification B. 19 
Acid Structure pKa1 
Citric Acid 
 
 
 3.08 
 
Formic Acid 
 
 
 
 
3.75 
 
Ascorbic Acid 
 
 
4.10 
Oxalic Acid 
 
1.23 
Conclusion 
Lennox-Gastaut syndrome is a devastating type of childhood epilepsy that can be treated 
with the drug rufinamide. This drug has been proven to be effective, but it has a low 
aqueous solubility that demands higher doses. Screening was conducted using solution and 
grinding methods to find other solid forms (such as co-crystals, co-amorphous, eutectic 
mixtures, solvate) to increase rufinamide’s solubility and bioavailability. Although 
screening did not result in the formation of a novel solid state, a novel synthesis of a 
metastable form of rufinamide, modification B, was discovered. The proposed method 
depended on solvent and excipient present. The molecular structure of rufinamide B, a 
poorly soluble antiepileptic drug, was determined and used in computer based co-crystal 
screening. The lack of novel solid states from the suggested co-formers implies that this 
method is not entirely reliable if co-crystal formation is challenging and molecular synthon 
approach should also be employed. Rufinamide is a small molecule with many potential 
sites for hydrogen bonding, and it has rotation about a CH2. Therefore, it should not be 
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disregarded completely for formation of a novel solid state. Also, due to the nature of 
Lennox-Gastaut syndrome, multiple prescriptions are used; perhaps drug-drug solid states 
should also be investigated.  
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Chapter 6 
Conclusion and Recommendations 
There is a clear need in the pharmaceutical industry to increase the solubility of new active 
pharmaceutical ingredients (APIs), since many of them are considered BCS 
(Biopharmaceutics Classification System) Class II and IV drugs. Increased solubility and 
dissolution rate of these APIs will lead to better bioavailability, reduced dosages, less waste 
and potentially fewer prescriptions; this all suggests savings for the pharmaceutical 
industry. In this thesis, three low solubility APIs (i.e. esomeprazole magnesium, curcumin 
and rufinamide) were all investigated for their ability to form novel solid states. This was 
done by screening with excipients that are approved for use in drugs and would expectantly 
interact with the API through intermolecular bonding. Formation of solid states was 
confirmed by a combination of powder and single crystal X-ray diffraction, differential 
scanning calorimetry, thermogravimetric analysis, solution nuclear magnetic resonance 
spectroscopy and dynamic vapour sorption. Further screening on these drugs can be 
conducted to find more novel states.  
Conclusions 
Esomeprazole magnesium is a low solubility drug used to treat chronic acid reflux. To 
improve this API, screening was conducted using solution crystallization and grinding 
techniques. What was obtained was a solvate with both water and 1-butanol present. High 
quality single crystals of this novel solid state were crystallized and the molecular 
structures were determined using X-ray diffraction. This is the first single crystal structure 
reported that displays esomeprazole coordinated to a metal center. The esomeprazole acts 
as a bidentate ligand, with three molecules coordinated to a single magnesium center. 
Magnesium cations are also shown to co-ordinate to water molecules, and water is 
furthermore shown to be filling the channels of the crystal lattice along with non-
stoichiometric amounts of butanol molecules. The covalently bonded waters are much 
more strongly kept in the lattice than those maintained by hydrogen bonding. When heated 
under vacuum the channel solvents were removed to reveal the dihydrate of esomeprazole 
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magnesium. This solvate will have similar solubility to the dihydrate since it has the same 
crystal structure. The discovery of this esomeprazole magnesium solvate could have 
applicability to the development of improved pharmaceutical solid dosage forms.  
Found in a variety of Asian cuisine, turmeric is a common spice that contains curcumin, a 
natural drug product that is found to have many health benefits. The use of curcumin in the 
pharmaceutical and food industries is often limited by its lack of aqueous solubility. In this 
thesis, screening for a novel solid state of curcumin with a variety of excipients was 
conducted. To narrow the search, a computer-based method was employed to predict which 
co-formers would form co-crystals with form I (most common and stable) curcumin. Folic 
acid dihydrate is one these predicted co-formers and was displayed to form a novel solid 
state with curcumin. After grinding with ethanol, a co-amorphous mixture was obtained 
and confirmed by PXRD (Powder X-ray Diffraction) and DSC (Differential Scanning 
Calorimetry). Repositioning of this mixture as a prenatal drug is possible since both folic 
acid and curcumin are used to treat a variety of pregnancy symptoms. This would save 
money and reduce the number of prescriptions needed. The co-amorphous mixture is also 
advantageous because it has improved dissolution rate over curcumin in aqueous solutions. 
After one hour, 175 mg/L of curcumin is dissolved in 40% ethanol from the co-amorphous 
mixture. This is a vast improvement over the 40 mg/L of form I curcumin after one hour. 
This mixture is also shown to be relatively stable and will keep its amorphous behaviour 
after 24 hours in solution at body temperature. Co-amorphous states in the pharmaceutical 
industry are relatively new and not well studied. The results confirm the validity of this 
solid state form as an improvement to APIs with low bioavailability. Additionally, given 
in this work is an alternative method of forming metastable form II curcumin. Crystals can 
be synthesized by slow evaporation from methanol in the presence of dextrose. Powder can 
be obtained from anti-solvent crystallization with water. This method is faster than current 
methods of producing form II curcumin and give a high purity yield. 
Rufinamide is a low solubility API that is used to treat a form of childhood epilepsy call 
Lennox-Gastaut syndrome that is characterized by multiple seizure types. While this API 
is proven to be effective, its solubility issues lead to increased dosages to generally young 
patients. To increase this undesirable characteristic, and essentially its bioavailability, 
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screening for the formation of a novel solid state was conducted. Many excipients were 
screened based on the molecular structures of a modified form of rufinamide and the 
metastable modification B. After extensive screening, no co-crystals, solvates, eutectics or 
co-amorphous mixtures were discovered. Perhaps the strong intermolecular bonding found 
in rufinamide is why it was not possible to include another molecule into its crystal lattice. 
Presented is a novel synthesis route for the crystallization of modification B as well as its 
molecular structure. This crystallization was found to be very dependent on the solvent 
(dimethyl sulfoxide) and excipient (citric acid) employed.  
Recommendations 
The screening of esomeprazole magnesium was successful in finding a novel solvate form; 
however, it was not practical or necessary to do dissolution rate or solubility studies 
because of the channel solvates. Since the solvent molecules that were not coordinated to 
magnesium were only weakly involved in intermolecular bonding, they would be easily 
removed and not problematic to quantify. This would lead to difficulties in solubility 
determination because molecular weight would vary for each sample. Also, since the 
molecular structure so closely matched esomeprazole magnesium dihydrate, it can be 
assumed to have a similarly improved solubility. Future work can be done to screen this 
API more thoroughly for other solid states. Perhaps it would be easier to form co-crystals 
or co-amorphous mixtures with esomeprazole as opposed to the magnesium salt. The 
molecular structure of the water/1-butanol solvate was very complex and could not be used 
to help determine a list of potential co-formers from Mercury. If single crystals could be 
produced that display the binding of the esomeprazole molecules to magnesium without 
solvent, then perhaps the software could be employed. This would help to narrow the 
search for potential API-excipient combinations as well as help improve understanding of 
the conceivable intermolecular interactions. The starting material used in the screening was 
the amorphous form of the pharmaceutical salt. Screening could possibly be conducting by 
starting with a crystalline form and comparing the result to screening with the amorphous 
form.  
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There were many differences in the predicted co-formers from Mercury software and the 
co-crystal formers that have been shown to form curcumin co-crystals in literature. If a 
greater understanding of these differences was made then perhaps it would be easier to 
know which excipients would be successful. More screening can be conducted with 
molecules that more closely represent those that have been shown to form novel solid 
states. Since curcumin is naturally occurring, maybe it can be viewed as an excipient for 
potential solid states with other drugs. The curcumin-folic acid dihydrate co-amorphous 
mixture (CUR-FAD) can be further studied. By running Raman and solid state nuclear 
magnetic resonance, perhaps a proposed bonding mechanism between the two molecules 
can be given. Stability studies that were not possible due to time constraints should be 
conducted for CUR-FAD for an extended period of time and under specific temperature 
and humidity conditions.  
There is definitely a need to further investigate the possibility of solid state formation with 
rufinamide. With its high potential for intermolecular hydrogen bonding and having Z’ 
value greater than 1, it should theoretically be readily available for synthesis of co-crystals, 
co-amorphous mixtures, eutectics or solvates. A wide range of excipients were attempted 
based on supramolecular synthons and computational suggestions. Possibly, a lesser 
emphasis should be placed upon the Mercury generated excipients, and a larger range of 
pharmaceutically approved excipients should be screened. Perhaps a literature survey of 
the unsuccessful co-crystallization of APIs should be conducted to further understand why 
no novel states were formed. Since there are known polymorphs of this API, a different 
modification could be isolated for attempts at solid state formation. It is also recommended 
that a wider range of solvents be attempted for crystallization experiments.  
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Appendices  
Appendix A Supporting Information for Chapter 3       
 
Figure A - 1: 1H NMR of the esomeprazole magnesium solvate. 
 
 
Figure A - 1: FTIR of the esomeprazole magnesium solvate. 
Wavenumber (cm-1) 
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Appendix B Calibration Curves for CUR-FAD Dissolution 
Studies 
When doing dissolution studies, UV-Vis is a viable means for determining the 
concentration of a solution. This technique requires the formation of a calibration curve 
from known concentrations that utilizes Beer’s Law (i.e. A = cl) to determine an 
extinction coefficient. This extinction coefficient is then used for the concentration 
calculation of unknown sample concentrations.  
 
Figure B - 1: Calibration curve and line of best fit for raw curcumin in 40% EtOH. 
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Figure B - 2: Calibration curve and line of best fit for raw folic acid dihydrate in 40% 
EtOH.  
 
Figure B - 3: Calibration curve and line of best fit for co-amorphous mixture of 
curcumin and folic acid dihydrate in 40% EtOH. 
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